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ABSTRACT
Developmental disorders (DDs) affect ~1% of the population worldwide. This being a
considerable amount, efforts are being made to elucidate the disease mechanisms.
One or several genetic factors cause 30-40% of DDs, and only 10% are caused by
environmental factors. The remaining 50% of DD patients go undiagnosed, mostly
due to a lack of diagnostic techniques. The cause in most undiagnosed cases is
thought to be a genetic factor or a combination of genetic and environmental
factors. Despite the surge of new technologies entering the market, their
implementation into diagnostic laboratories is hampered by costs, lack of
information about the expected diagnostic yield, and the wide range of selection.
This study evaluates new microarray methods in diagnosing idiopathic DDs,
providing information about their added diagnostic value.
Study I analysed 150 patients, with idiopathic DD and normal karyotype, by array
comparative genomic hybridization (array CGH, 44K and 244K), with a subsequent
18% diagnostic yield. These results are supported by other studies, indicating an
enourmous added diagnostic value of array CGH, compared with conventional
cytogenetic analysis. Nevertheless, 80% of the patients remained undiagnosed in
Study I. In an effort to diagnose more patients, in Study IV the resolution was
increased from 8.9 Kb of the 244K CGH array to 0.7 Kb, by using a single-nucleotide
polymorphism (SNP) array. However, no additional pathogenic changes were
detected in the 35 patients assessed, and thus, for diagnostic purposes, an array
platform with ca 8.9 Kb resolution appears adequate.
The recent vast increase in reports of detected aberrations and associated
phenotypes has enabled characterization of several new syndromes – first based on
a common aberration and thereafter by delineation of common clinical
characteristics. In Study II, a familial deletion at 9q22.2q22.32 with variable
penetrance was described. Despite several reports of aberrations in the adjacent
area at 9q associated with Gorlin syndrome, the patients in this family had a unique
phenotype and did not present with the syndrome. In Study III, a familial duplication
of chromosome 6p22.2 was described. The duplication caused increased expression
of an important enzyme of the γ-aminobutyric acid (GABA) degradation pathway, 
causing oxidative stress of the brain, and thus, very likely, the mild intellectual
disability of these patients. These two case studies attempted to pinpoint candidate
genes and to define the pathogenic mechanism causing the clinical characteristics of
the patients. Presenting rare genetic and clinical findings to the international
science and medical community enables interpretation of similar findings in other
patients.
The added value of molecular karyotyping in patients with idiopathic DD is evident.
As a first line of testing, arrays with a median resolution of at least 8.9 Kb should be
considered and further characterization of detected aberrations undertaken when
possible. Diagnostic whole-exome sequencing may be the best option for patients
who remain undiagnosed after high-resolution array analysis.
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TIIVISTELMÄ
Kehityshäiriöiden maailmanlaajuinen esiintyvyys on n. 1 %. Tämä on niin merkittävä
määrä, että niiden syntymekanismin selvittäminen on hyvin perusteltua. Yksi tai
useampi geneettinen tekijä aiheuttaa n. 30–40 % kehityshäiriöistä ja vain 10 %
johtuu ympäristötekijöistä. Lopulla 50 %:lla potilaista taudin etiologia jää avoimeksi
diagnostisten menetelmien puuttumisen takia. Valtaosa näistä tapauksista
arvioidaan aiheutuvan joko geneettisistä syistä tai geneettisten ja
ympäristötekijöiden yhteisvaikutuksesta. Markkinoille tulleiden lukuisten, uusien
tutkimusmenetelmien käyttöönottoa diagnostisissa laboratorioissa vaikeuttaa
hintataso, puutteellinen tieto diagnostisesta tarkkuudesta, sekä monikirjoinen
tarjonta. Tämän tutkimuksen tavoitteena oli arvioida uusia mikrolevymenetelmiä ja
niiden tuoma hyöty idiopaattisten kehityshäiriöiden etiologian selvittämisessä.
Ensimmäisessä osajulkaisussa tutkittiin 150 potilasta joilla oli idiopaattinen
kehityshäiriö ja normaali karyotyyppi. Käyttämällä vertailevaa genomista
hybridisaatio -mikrolevymenetelmää (VGH-mikrolevy, 44K ja 244K) todettiin 18 %:lla
patogeeninen muutos. Muutkin tutkijaryhmät ovat päätyneet vastaavaan tulokseen,
joten VGH-mikrolevyn käyttöä diagnostiikassa voidaan pitää perusteltuna
verrattuna perinteisiin sytogeneettisiin menetelmiin. Ensimmäisessä osajulkaisussa
jäi kuitenkin edelleen 80 % potilaista ilman etiologista diagnoosia. Tämän takia
lisäsimme neljännessä osajulkaisussa tutkimusmenetelmän resoluutiota 8,9 Kb:stä
(244K) 0,7 Kb:iin käyttämällä yhden-nukleotidin polymorfismi
mikrolevymenetelmää. Tutkittujen 35 potilaiden kohdalla ei tullut ilmi uusia
patogeenisia muutoksia, joten diagnostiikkaa varten, noin 8.9 Kb:n resoluution
omaava platformi näyttäisi olevan riittävän suuri.
Kehityshäiriöiden kromosomaalisista muutoksista ja niihin liittyvistä fenotyypeistä
on viime aikoina julkaistu runsaasti uutta tietoa. Tämän avulla on pystytty
tunnistamaan uusia oireyhtymiä – ensisijaisesti yhteisen genettisen muutoksen
perusteella, ja vasta tämän jälkeen yhteisten kliinisten piirteiden perusteella.
Toisessa osajulkaisussa kuvattiin familiaalinen deleetio 9q22.2q22.32, vaihtelevalla
penetranssilla. Vaikka läheisellä 9q-alueella löydetyt muutokset monesti liitetään
Gorlin-oireyhtymään, tässä perheessä potilailla oli uniikki fenotyyppi, joka ei
viitannut tähän oireyhtymään. Kolmannessa osajulkaisussa kuvattiin familiaalinen
duplikaatio kromosomissa 6p22.2. Muutos aiheuttaa GABAn hajottamissyklissä
tärkeän entsyymin lisääntyneen ekspression. Tämä johtaa aivoissa oksidatiiviseen
stressiin, mikä todennäköisesti selittää potilaiden lievän kehityshäiriön. Näiden
kahden osatyön pyrkimyksenä oli määrittää kandidaattigeenejä, sekä potilaiden
kliinisten piirteiden taustalla olevat patogeeniset mekanismit. Harvinaisten
geneettisten ja kliinisten löydösten julkaiseminen kansainvälisesti, hyödyttää
vastaavanlaisten muutosten tulkitsemista. Molekyylikaryotyypityksen lisähyöty
idiopaattisten kehityshäiriöiden tutkimisessa on selvä. Ensisijaisena menetelmänä
tulisi harkita mikrolevyä, vähintään 8.9 Kb:n resoluutiolla. Löydettyjen muutosten
lisäselvittäminen on suositeltavaa. Mikäli korkean resoluution mikrolevytutkimus ei
tuota tulosta, saattaa koko eksomin sekvensointi olla perusteltua.
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INTRODUCTION
Developmental disorder (DD) describes a group of disorders caused by errors in the
foetal developmental process, so-called inborn defects. DDs have a major impact on
the lives of affected individuals and their families. Receiving the correct diagnosis is
important for several reasons. In genetic counselling of parents and relatives, a
diagnosis may help to estimate recurrence risk. A diagnosis can also improve the
medical care of the child when the prognosis of the disorder is known, despite the
fact that for many disorders no therapeutic medical interventions are available. A
diagnosis also gives parents the opportunity to contact other families and support
groups for the disorder.
Despite improvements in diagnostic technology during the past decade, only half of
the patients receive an aetiological diagnosis (Hunter 2000, van Karnebeek et al.
2005). This indicates the importance of applying new analysis methods for more
comprehensive characterization of the genetic changes involved in the aetiology of
DD.
During recent years microarray-based comparative genomic hybridization (array
CGH) and single-nucleotide polymorphism (SNP) arrays have rapidly become the
foremost diagnostic approaches for identifying genetic aberrations underlying DDs,
complemented by conventional karyotyping. With advancements in microarray
technology, it is now possible to screen the whole genome for genetic aberrations
at a very high resolution. A single microarray yields far more information on copy
number variations (CNVs) of the whole genome than karyotyping or individual
locus-specific fluorescence in situ hybridization (FISH). New insights into the role of
previously unidentified chromosomal aberrations, uniparental disomy (UPD), micro
RNAs (miRNA), and genomic methylation as a cause of DD are now emerging.
Microarray analysis has enabled the identification of novel, recurrent microdeletion
syndromes, increasing knowledge about the aetiology of DDs with daunting speed.
Many studies have by now found apparent pathogenic CNVs using array CGH or SNP
arrays in 10-20% of patients with idiopathic DD and a normal karyotype (Shaffer and
Bejjani 2010a).
This study evaluates the usefulness of new molecular array analysis methods in
diagnosing patients with idiopathic ID and/or dysmorphic features and/or
malformations and a normal karyotype and attempts to uncover the aetiological
factors underlying the disorders. This is the first study of its kind in Finland, and its
results will support clinical diagnostic work and facilitate the implementation of new
analysis methods into diagnostic laboratories. The study hypothesis is that new
molecular analysis methods will enable more efficient detection of pathogenic
genetic factors causing DDs, relative to conventional analysis methods. New
syndromes are anticipated to be identified, improving patient treatment through
better knowledge of characteristic clinical symptoms.
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LITERATURE REVIEW
1. DEVELOPMENTAL DISORDERS
1.1 DEFINITION
DDs include ID – a state of intellectual disability with an intelligence quotient (IQ)
<70 – as well as a wide range of congenital abnormalities. ID is subdivided into
groups, depending on the severity of social impairment and the IQ of the patient, as
indicated in Table 1. Fortunately, the most common subgroup is mild ID, as these
patients are able to lead a relatively independent life.
Congenital abnormalities refer to inborn structural defects. These can be further
distinguished, depending on the mechanism of formation. A malformation, the
abnormal fomation of tissue (e.g. polydactyly, cleft palate), can be caused by
genetic or environmental factors. Malformation of several organs or body parts are
referred to as a malformation syndrome. Dysplasia is the aberrant organization of
cells into tissues, such as aberrant development of a tissue type (e.g. diastrophic
dysplasia or dwarfism), and is mostly caused by monogenic factors. The distinction
between malformations and dysplasias is not absolute. Deformations are
abnormalities in form or function of a body part, as a result of mechanical forces
acting on normal tissue. An example of this would be compression, due to structural
abnormalities of the uterus, leading to deformation of the skull (plagiocephaly). A
disruption is the destruction of a normally developed tissue or organ (e.g. foetal
alcohol syndrome), caused by environmental factors, such as infections or anoxia
(Epstein et al. 2008).
Developmental delay is a term mainly used for young patients (<5 years of age)
whose development is ongoing and the full clinical spectrum is not yet
determinable. Children with developmental delay will not necessarily become
mentally retarded (Shevell et al. 2003).
Table 1. Subgrouping of ID based on IQ -levels. Mental age indicates the
level of cognition of patients (1)World Health Organization ICD-10,
accessed 10.10.2011; 2)American Psychiatric Association DSM-IV, 2000).
Severity1 IQ1 Mental age1
(years)
~% of world ID
population2
Mild 50-69 9-12 85
Moderate 35-49 6-9 10
Severe 20-34 3-6 3-4
Profound < 20 < 3 1-2
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1.2 PREVALENCE
DDs occur relatively frequently in the general population, with a prevalence of
about 1%. In Finland, there are reportedly some 40 000 developmentally disordered
individuals, corresponding to approximately 0.8% of the Finnish population (Finnish
information center on intellectual and developmental disabilities, accessed
10.10.2011). The lower prevalence of DDs in Finland, compared with the general
world population, is likely due to the lack of such social and economic problems as
malnourishment, which is a significant cause of mild ID in developing countries
(Chiurazzi and Oostra 2000). Also affecting these figures are the efficient diagnostic
procedures used during pregnancy to detect abnormalities. However the incidence
of Down syndrome has risen as a result of the increasing age of birth-giving
mothers. Of all Down children, 42.7% were born to mothers aged over 35 years
(National Institute for Health and Wellfare, accessed 10.10.2011). In a study from
2007 based on national and social benefits registers in Finland, the prevalence of ID
was 0.7% (Westerinen et al. 2007).
In Finland, from 1993-2008, congenital abnormalities were detected in 3.3% of live
births, 18.1% of stillbirths, 27.1% of perinatal deaths, and 44% of infant deaths. On
average, 236 pregnancies are terminated each year due to congenital abnormalities
(National Institute for Health and Wellfare, accessed 10.10.2011).
In comparison, in 2006 in the United States, the leading cause of all infant deaths
was congenital abnormalities (21%). Other major causes were low birth weight and
short gestation (17%), sudden infant death syndrome (8%), maternal complications
during pregnancy (6%), and injury (4%) (Mathews and MacDorman 2010). This
indicates that factors other than congenital abnormalities proportionately cause
more infant deaths in the United States than in Finland.
The prevalence of registered cases of congenital abnormalities in Europe between
1999 and 2008 was 2% (202.12/10 000 births), the most common being
abnormalities of the heart (29.9%), limbs (18.3), urinary tract (15.6%), and nervous
system (11.0%) (Loan et al. 2011).
Since 1963, the National Institute for Health and Wellfare in Finland has collected
data on the prevalence of congenital abnormalities in an effort to prevent similar
disasters as the one caused by the Thalidomide drug in the 1960s. In 1993, the
operation of the registry was updated, as data reporting from hospitals improved.
This led to a vast increase in the detection of congenital abnormalities in the 1990s,
despite no actual rise in prevalence (National Institute for Health and Wellfare,
accessed 10.10.2011).
The International Clearinghouse for Birth Defects Surveillance and Research
(www.icbdsr.org) and the European Surveillance of Congenital Anomalies
(www.eurocat-network.eu) are two international organizations that monitor the
prevalence of congenital abnormalities internationally and in Europe, respectively.
These registries also include Finnish data.
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2. CHROMOSOMAL AETIOLOGY
Development of a functional body and mind requires delicate control by a wide
range of genes in addition to a healthy environment. It is crucial that certain genes
function at the correct time and at a correct dosage during development, and any
disruptions to this sensitive system may have poor outcomes for the developing
foetus. The aetiology of DDs is generally divided into three main categories: genetic
factors, environmental factors, and unknown factors. These are presented in detail
in the following sections.
Genetic factors are estimated to cause 33% of all DDs, 20% by polygenic, 6% by
chromosomal, and 7.5% by monogenic aberrations (Winter 2006). However, these
figures may change over time, as new technologies are implemented and new
genetic aberrations are detected.
Chromosomal factors cause changes in the total number of chromosomes, such as
polyploidy and aneuploidy, as well as changes in chromosome structure, such as
deletions, duplications, inversions, substitutions, and translocations, thereby
creating an imbalance in the total amount of DNA.
2.1 PLOIDIES
Human chromosomes are counted in sets of 23 (n=23), a single set being referred to
as a haploid set. A normal human has two sets of chromosomes referred to as a
diploid set (n=46). Chromosomes are defined as either autosomes (numbered 1 to
22) or sex chromosomes (X or Y). Females have 44 autosomes and two X-
chromosomes (46, XX) and men have 44 autosomes an one X and Y-chromosome
(46, XY). Ploidies are changes in the total number of chromosomes present in a cell,
which differ from the normal human diploid set of 46.
2.1.1 POLY PL OIDY
Polyploidy refers to the presence of three or more complete sets of chromosomes,
such as triploidy (e.g. 69,XXX) or tetraploidy (e.g. 92,XXYY), instead of the normal
diploid set (46,XX or XY).
Although polyploidy is the natural state of several plant species, it is much rarer in
animals, and in humans it is an unnatural occurrence (Otto and Whitton 2000).
Triploidy is very rare in live-born children and tetraploidy even more so, with only
nine reported patients (Stefanova et al. 2010). These polyploid conditions usually
lead to death of the infant within days or months of birth. Long-term survival is
possible only if the polyploidy presents in a mosaic state. In fact, >99% of polyploid
foetuses lead to miscarriage, acounting for 15-20% of all miscarriages (Snijders et al.
1995, Stefanova et al. 2010).
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Triploidy can be caused by two sperms or a diploid sperm fertilizing a haploid oocyte
or by a haploid sperm fertilizing a diploid oocyte. Diploid sperms or oocytes arise
through non-disjunction of the chromosome set during the first or second meiotic
division in oogenesis or spermatogenesis, creating an oocyte or a sperm with a
diploid set of chromosomes instead of the normal haploid (McFadden et al. 2002).
Tetraploidy can be caused by two sperms or a diploid sperm fertilizing a diploid
oocyte, by normal fertilization between a haploid sperm and oocyte, followed by
normal chromosme division but failure of cytoplasmic cleavage, or by fusion of two
normal zygotes and their nuclei into one embryo (Baumer et al. 2003). The fusion of
zygotes in this context is not to be confused with chimeras, in which two zygotes
create a single embryo but the two chromosome sets are not fused, but rather give
rise to mosaicism (Malan et al. 2006). Tetraploid karyotypes 96,XXYY and 96,XXXX
are more common than karyotypes 96,XXXY and 96,XYYY. Tetraploidy is, however,
extremely rare in humans (Baumer et al. 2003). Polyploidy may also arise in somatic
cells, and it is very common in different types of tumours.
Polyploidy is best studied by chromosomal karyotyping or FISH analysis.
2.1.2 ANEUP LOIDY
Aneuploidy refers to having an additional chromosome or lacking a chromosome of
the diploid set. Aneuploidies are presumably caused by non-disjunction during
mitosis. The two forms of aneuploidies are monosomy and trisomy.
Monosomy refers to the lack of one chromosome of a chromosome pair. Lacking of
a whole chromosome is fatal, except in the case of monosomy of the X-
chromosome (Turner syndrome, 45, X).
Trisomy refers to having one extra copy of a chromosome. Trisomies cause
increased expression of several genes and are almost always lethal. Only children
with trisomies of gene-poor chromosomes or sex chromosomes can survive. There
are only a few known trisomies detected in live-born children, i.e. Down (trisomy
21), Edward (trisomy 18), and Patau (trisomy 13) syndromes (Loane et al. 2011), as
well as trisomy 9 (Kannan et al. 2009) and 22 (Mokate et al. 2006). The latter four
usually cause death in infancy. Whole-chromosome aneuploidies of other
autosomes have such a severe outcome that the foetus does not survive, but is
spontaneously aborted. Other trisomies may be viable only when present in a
mosaic state.
Aneuploidies of the sex chromosomes, such as Klinefelter (47,XXY) (Wikström et al.
2011) and Triple-X (47,XXX) (Tartaglia et al. 2010), have less severe outcomes and
are mostly indistinguishable phenotypically. Only 10% of Triple-X cases are actually
diagnosed (Tartaglia et al. 2010). Other rare forms of sex chromosome aneuploidy
include XXXX, XXXXX, XXXXY, XXXY, XXXYY, XXYY, XXYYY, XYYY, XYYYY and XYY (Linden
at el. 1995).
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Suspected aneuploidies, such as Down syndrome, can be studied by targeted
testing, including trisomy-PCR, FISH, or BACs on beads. Aneuploidy screening of the
whole genome can be done by use of standard or molecular karyotyping.
2.1.2.1 MOS AI CISM
Mosaicism refers to the coexistence of two cell populations in one individual,
developed from a single zygote; one with a normal chromosome set (46,XX or 46,
XY) and the second with a different chromosome set. The other cell population may
harbour mutations, rearrangements, or structural aberrations, the most common
being mosaic aneuploidy (Conlin et al. 2010). Mosaicism may occur in somatic or
germline cells; both types are caused by mitotic errors. Germline mosaicism is
restricted to the gonads and as such does not affect the phenotype of the carrier,
but conveys an increased risk of transmitting a genetic aberration to the offspring.
While mosaicism stems from a single zygore, chimerism refers to the fusion of two
zygotes into one embryo, without fusion of the nuclei (Malan et al. 2006).
Chromosomal mosaicism is common and often identified by a subtle phenotypic
similarity of the patient to a known chromosomal disorder. Subsequent studies of
different tissue samples can reveal the mosaic state of cell populations (Youssoufian
and Pyeritz 2002). The most common form of mosaicism is trisomies of
chromosomes 8, 9, 14, 15, and 22 (Shaffer and Bejjani 2010a). Mosaic chromosomal
aneuploidies are reportedly detected in 50% of preimplantation embryos, 1% of
chorionic villi samples, 0.2-0.3% of amniotic fluids, and 0.1% of newborns
(Rodriguez-Santiago et al. 2010).
Interestingly, mosaicism has recently been shown as a cause for variable phenotypic
expression in more than 30 monogenic disorders. This overthrows the general view
that phenotypic variability is caused solely by differences in DNA alterations
(Gottlieb et al. 2001). Mosaicism has also been described in cancer, mitochondrial
disorders, and as a cause of phenotypic variability in twins (Youssoufian and Pyeritz
2002).
Detection of mosaicism is difficult since it is mostly restricted to certain a type of
tissue. If present in blood, detection is dependent on the method of analysis.
Karyotyping can detect chromosomal mosaicism, unless it is present in a very low
number of cells (Conlin et al. 2010). Array CGH requires that at least 30% of the cells
are representative of the aberrated cell line in order for the analysis program to
detect the change. If a change is detected, the percentage of mosaic cells can be
calculated by further studies using targeted FISH analysis of different tissue
samples.
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2.2 STRUCTURAL ABERRATIONS
Coined in 1998 by James Lupski, the concept of genomic disorders refers to a group
of genetic diseases caused by structural rearrangements of the genome, such as
deletions, duplications, or disruption of genes that are dosage-sensitive, rather than
DNA base-pair (bp) changes (Lupski 1998). These disorders occur sporadically or de
novo. Patients with a genomic disorder may have similar, but not necessarily
identical, aberrations that cause a varying clinical spectrum.
The rearrangements can cause a deletion and/or duplication that, depending on the
size of the genomic segment as well as the number of dosage-sensitive genes
involved, lead to a Mendelian disease, a contiguous gene syndrome, or a
chromosomal disorder (Figure 1). Although Mendelian diseases are generally
caused by mutations to single genes, deletions or duplications of that gene may
manifest the same disease (Stankiewicz and Lupski 2002).
FIGURE 1. DIFFERENT SIZES OF REARRANGEMENTS CONSTITUTING GENOMIC DISORDERS. The x-axis
represents the number of bps involved in the rearrangement. Depending on the size of the
rearrangement and the number of dosage-sensitive genes involved, the resulting genomic
disorder may be a Mendelian disease, a contiguous gene syndrome, or a chromosomal
disorder. Reprinted from TRENDS in Genetics, Vol.18(2), Stankiewicz P and Lupski R,
Genome architecture, rearrangements and genomic disorders, pp.74-82, Copyright (2002),
with permission from Elsevier.
2.2.1 DELETI ONS , DU P LICATI ONS , INV ERSI ONS , SU BSTITUTI ONS ,
AND TRA NSL OCATI ONS
Chromosomal deletions and duplications can arise as a consequence of non-allelic
homologous recombination (NAHR, Section 4.2.2), which is an unequal cross-over in
meiosis between paralogous (i.e. similar) sequences (Lupski 1998). Deletion or
duplication of dosage-sensitive genes is likely to be harmful, and large deletions and
duplications can even lead to spontaneous abortion. As stated by Gardner and
Sutherland “...anything but 100% of the normal amount of (at least autosomal)
genetic material produces less than 100% normal phenotype” (Gardner and
Sutherland, 2004).
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FIGURE 2. COMMON CHROMOSOMAL REARRANGEMENTS, including deletion of a chromosomal
segment, duplication of a segment, inversion of a segment in the same chromosome,
substitution of a segment from one chromosome to another, and translocation, which is
the exchange of segments between two different chromosomes. This image is reprinted
courtesy of the National Human Genome Research Institute.
Deletions or duplications at the end of a chromosome are referred to as terminal,
those close to the end as subtelomeric, and those in the middle of a chromosome as
interstitial deletions (Gardner and Sutherland 2004). Duplications and deletions that
are detectable by standard karyotyping cause many of the well-known syndromes,
e.g. Wolf-Hirschhorn syndrome; these are all listed in the Online Mendelian
Inheritance in Man (OMIM) database.
Structural rearrangements involving the physical reorganization of chromosomal
segments include translocations, inversions, and insertions (also termed
substitutions, see Figure 2). This exchange of DNA material between two locations
of a chromosome or between chromosomes can be either balanced, if there is no
change in DNA copy number, or unbalanced, if a deletion or duplication has occured
at the breakpoint. Even balanced rearrangements may be pathogenic if they disrupt
a gene at the breakpoint, if genes are put under the regulation of foreign elements,
or if they create a fusion between two genes - possibly creating a new transcript.
Structural rearrangements are best studied by karyotyping or FISH, as they cannot
be distinguished by microarray analysis. It is also possible to detect rearrangements
by sequencing, using the paired-end technique.
2.2.1.1 M ICR O DE L ETI O NS AN D -DU P L ICAT IO N S
Patients with a normal karyotype in cytogenetic testing may have aberrations at a
submicroscopic level that are difficult to detect by standard karyotyping due to
limited resolution (~5 Mb). Such small changes are termed microdeletions and
microduplications (collectively called microaberrations). They can also be referred
to as subchromosomal or submicroscopic aberrations. A deletion or duplication of
consecutive genes on a chromosome causes what is referred to as contiguous gene
syndromes. Changes to the total amount of DNA cause a shift in the expression level
of some genes, whether an increase or decrease, and may also affect the
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surrounding genomic areas by way of gene disruption (see Section 6.1.2). If dosage-
sensitive genes are involved in the aberration, the effect may be pathogenic.
In recent years, a vast increase has occured in the number of publications reporting
new microaberrations associated with DDs. Until recently, syndromes were
delineated based on shared clinical features, and only thereafter were the
pathogenic mechanism discovered. Nowadays, it is more common to group
together patients with a similar genetic aberration and then characterize the
common clinical features. Microaberrations are often flanked by segmental
duplications, enabling recurrent rearrangement at the same chromosomal location
(rearrangement hotspots, see Section 4.2.2).
Compared with microdeletions, interpreting the pathogenic effect of
microduplications can be more difficult, and microduplications perhaps were not
considered as relevant until the first cases of a reciprocal duplication syndrome to
Smith-Magenis was described: the Potocki-Lupski syndrome (Potocki et al. 2000,
2007). Currently, 14 microduplication syndromes or susceptibility loci have been
described that are reciprocal to a microdeletion syndrome, but cause different
phenotypic features (DatabasE of Chromosomal Imbalance and Phenotype on
Humans using Ensemble Resources - DECIPHER, OMIM, Berg et al. 2010).
Microduplications generally have milder and more variable phenotypic effects than
the reciprocal microdeletion phenotype. This may be caused by incomplete
penetrance (see Section 6.2).
One problem in establishing microduplication syndromes seem to be the discerning
of a common phenotype, as some individuals at the very mild range of the
phenotypic spectrum might never be tested by high-resolution arrays, thus making
the disease characterization incomplete. The difficulty in determining a very mild
phenotype also means that some individuals with a microduplication may be
considered as phenotypically normal if not carefully examined, leading to a general
conception that the detected genomic aberration is polymorphic (Berg et al. 2010).
FIGURE 3. A CHROMOSOMAL OVERVIEW OF ABERRATIONS CAUSING CONTIGUOUS GENE
SYNDROMES. Deletions are shown in red, duplications in green. Image from the DECIPHER
database reprinted under the Creative Commons license.
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There are 58 acknowledged microaberration syndromes; these can be found in the
DECIPHER database (www.decipher.sanger.ac.uk, Figure 3). Some are well
established, both clinically and genetically, such as Wolf-Hirschhorn (4p16.3
deletion) and Angelman syndrome (15q11q13 deletion), while others are relatively
new, such as the 17q21.3 recurrent microdeletion syndrome, which was first
described in 2006 by three independent research groups (Koolen et al. 2006, Sharp
et al. 2006, Shaw-Smith et al. 2006).
Microaberrations are detectable by targeted FISH analysis, provided that the
chromosomal location is known. Currently, the best method of detection is,
however, array CGH or SNP array analysis, both widely applied methods throughout
diagnostic laboratories. Recent work on genomic microdeletions and
microduplications has shown that approximately 10-20% of patients with a normal
karyotype have a chromosomal aberration subsequently detected by use of array
analysis (Vissers et al. 2003, Shaw-Smith et al. 2004, de Vries et al. 2005a,
Schoumans et al. 2005, Friedman et al. 2006, Menten et al. 2006, Rosenberg et al.
2006, Aradhya et al. 2007, Baross et al. 2007, Fan et al. 2007, Shen et al. 2007,
Wagenstaller et al. 2007, Lybaek et al. 2008).
2.3 MUTATIONS
Mutations are changes in one or a few single bps of the DNA sequence. They are
classified as deletions, insertions, or substitutions (also referred to as point
mutations, Figure 4). The pathogenic mechanism of any mutation is defined by its
effect on the codon and, consequently, the amino acid and protein structure.
Mutations can arise spontaneously, e.g. by errors in replication, or by induction of
teratogenic factors. The DNA repair mechanism generally removes harmful
mutations, but sometimes this mechanism fails to detect the change.
Deletions remove one or more nucleotides from the DNA sequence. This may also
alter the reading frame of the amino acid sequence. Insertion is the addition of one
or more nucleotides to the DNA sequence. This may cause splice site alterations or
frameshifts in the reading of the amino acid sequence. Substitution is the exchange
of one nucleotide for another, creating a new codon. If the new codon encodes the
same amino acid, it is a silent mutation, as it has no consequence for the protein
function. If it encodes a different amino acid it is a missense mutation and may be
pathogenic. If it changes into a stop codon, this will truncate the protein, likely
rendering it dysfunctional, and this is referred to as a nonsense mutation.
Monogenic disorders, also called Mendelian diseases, are caused by mutations in, or
deletions of, a single gene. The affected genes are mostly regulatory and will affect
the transcription of other genes or signalling pathways (Chiurazzi and Oostra 2000).
Mendelian diseases segregate as autosomal recessive, autosomal dominant, X-
linked, or Y-linked. There are estimatedly over 10 000 monogenic disorders
worldwide (World Health Organization, accessed 7.3.2011).
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FIGURE 4. COMMON MUTATIONS IN MONOGENIC DISORDERS. All mutations affect only one or a
few bps of the nucleotide sequence by either deletion, insertion, or substitution. This
image is reprinted courtesy of the National Human Genome Research Institute.
Known mutations are best studied by targeted PCR or sequencing, while screening
for unknown mutations requires efficient methods such as whole-genome
sequencing and genotyping.
3 OTHER AETIOLOGICAL FACTORS
3.1 EPIGENETIC FACTORS
Epigenetic factors are meiotically or mitotically heritable alterations to the DNA
structure and the expression of genes not involving changes to the DNA sequence.
Three factors can be classified as such: DNA methylation, histone modification, and
small non-coding RNAs. All factors may be tissue-specific and developmentally
regulated. The effect of epigenetic factors is reversible even in fully differentiated
cells.
3.1.1 DNA METHYLAT ION
DNA methylation is required for normal development and is seen in different
processes such as gene repression, imprinting, X-chromosome inactivation,
suppression of repetitive elements, and carcinogenesis.
DNA methylation is a mechanism for silencing gene expression. The functional
mechanism of methylation consists of the addition, by DNA methyltransferase
enzymes, of a methyl group to the 5’-position of a cytosine residue in the DNA
sequence, and only occurs on cytosines that lie next to guanines (CpG
dinucleotides). CpGs that are clustered in promoter areas are referred to as CpG
islands. CpGs elsewhere are usually located in repetitive or centromeric stretches of
DNA. While the CpG islands in general are not methylated, CpGs outside the islands
mostly are in order to maintain a stable chromosome structure and to prevent
translocations. CpG island methylation silences the gene that is regulated by the
promoter (reviewed by Urdinguio et al. 2009).
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X-chromosome inactivation is a mechanism whereby one of the two copies of the
female X-chromosome is randomly inactivated (lyonization) (Lyon 1961). This means
that females are mosaics for two cell lines: one with a paternal and the other with a
maternal active X-chromosome (Ørstavik K, 2007). The mechanism of X-inactivation
is hypothesized to start from an X-inactivation center (XIC) on the X-chromosome
that is to be inactivated. In XIC, the XIST gene produces a non-coding RNA transcript
that blocks transcription of most, but not all, genes of the inactivated X-
chromosome (reviewed by Yang et al. 2011). When one X-chromosome is
preferentially inactivated in more than 80% of the cells, this is referred to as skewed
X-inactivation, as opposed to nomal random X-inactivation. In female carriers of an
X-linked disorder, skewed X-inactivation can lead to the unfavourable expression of
the disease-carrying chromosome (Ørstavik K, 2007).
Dysfunction mutations of genes important to the epigenetic machinery can cause
DDs, such as Rubinstein-Taybi (CBP), Coffin-Lowry (RSK2), and Alpha-Talassemia X-
linked MR syndrome (ATRX) (Urdinguio et al. 2009).
The methylation pattern can be studied by different mechanisms, including
androgen receptor PCR and methylation-specific PCR (MSP). In androgen receptor
PCR, the two X-chromosomes can be differentiated by PCR analysis. The first exon of
the androgen receptor gene (AR), contains a highly polymorphic (CAG)n repeat.
About 100 bp to either side of the repeat are methylation-sensitive restriction sites
for the HhaI and HpaII enzymes. The DNA sample is digested using one of the
restriction enzymes, and the template is PCR-amplified. Only the methylated
template will amplify, while the unmethylated template is digested. Due to the
heterozygous repeat, it is possible to distinguish the paternally and maternally
inherited X-chromosome, as these are likely to have repeats with different lenghts.
(Allen et al. 1992). In MSP, RNA is converted to cDNA in a reaction with sodium
bisulphite that converts unmethylated cytosines of CpGs into uracil (UpG), while
methylated cytosines remain unconverted. This is followed by PCR using primers
specific for both methylated and unmethylated DNA. Subsequent comparison of
cDNA and genomic DNA can reveal the methylation status of the target sequence
(Herman et al. 1996). Other methods include immunoprecipitation of methylated
DNA and subsequent array (MeDIP-chip) (Weng et al. 2009) or sequencing (MeDIP-
seq) analysis (Ruike et al. 2010).
3.1.2 UNI PAR ENTAL D ISOMY
When a chromosome or a segment thereof has originated from only one parent,
instead of two, this is referred to as UPD (Engel 1980). UPDs cannot be distinguished
at the cytogenetic level, as the normal karyotype of 46,XX/XY will remain. At a
molecular level, however, differences or similarities can be found between the two
chromosomes or chromosomal segments. The parental origin of the chromosome is
detectable by reading either polymorphic satellite markers or SNPs. If the
chromosomes or segments have the same polymorphic markers (haplotype) as one
of the chromosomes from one parent, this is termed uniparental isodisomy. If the
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haplotype is the same as the chromosome pair of one parent, this is termed
uniparental heterodisomy (Figure 5) (Kotzot 2008).
Whole-chromosome UPD can be generated by monosomy rescue, post-fertilization
error, trisomy rescue, and gamete complementation (Figure 5) (Yamazawa et al.
2010). Trisomy rescue is the most common mechanism of UPD formation; gamete
complementation in theory is possible, but in practice is very rare.
A UPD caused by meiotic errors can disturb development, whereas UPDs caused by
mitotic errors are common in cancer development. There are no reports of
recurrent UPDs (Kotzot 2008, Engel 2006); thus, the risk of inheritance appears low.
Allelic homozygosity of genomic segments are mostly benign occurrences and quite
frequent in the human genome. In founder populations, such as the Finns, chances
are high that two people will have the same set of haplotype blocks, referred to as
linked segregation (Kristiansson et al. 2008). Segmental UPD can arise as a result of
equal somatic crossing-over between the paternal and maternal chromosomal
homologue (Figure 5, 2b) (Engel 2006). Another mechanism is meotic non-
disjunction, producing a disomic gamete that is fertilized by a monosomic gamete,
recombination occurs, and one of the original disomic chromosomes is lost. In
segmental UPD, the involvement of imprinted genes or mutations, leading to
overexpression or complete silencing of a gene, may confer a developmental risk.
An imprint is an epigenetic “tag”, marking genes as either maternally or paternally
inherited. Imprinted loci are subject to silencing by methylation, and this
methylation is sustained throughout the lifetime of all somatic cell lineages (Arnaud
2010). In germline cells, the imprint is completely erased and reset; in early
oogenesis, both chromosomes of a pair are marked with a maternal imprint, and in
early spermatogenesis all chromosomes receive a paternal imprint (Chamberlain
and Lalande 2010). After fertilization, chromosomes are readily methylated,
according to their parental imprint. Thus, only one allele is expressed, either the
paternally or maternally inherited copy. Only a small fraction of the whole genome
is subject to imprinting. The human genome is estimated to contain only 100
imprinted genes (0.33% out of 30 000 genes) (reviewed by Tycko 2010). UPD in
combination with imprinted genes implicated in disease is found on chromosomes
6, 7, 11, 14, 15, and 20 (Engel 2006).
A few well-established syndromes, e.g. Cystic fibrosis, Prader-Willi, Angelman,
Beckwith-Wiedmann, and Silver-Russel syndrome, are caused by UPD and a
subsequent imprinting effect. Often, these UPD phenotypes can also arise by other
genetic defects such as a deletion or methylation of the disease-critical region. UPD
of chromosome 14 is associated with characteristic phenotypes, depending on the
parent of origin. The overexpression or absence of parent-specific transcripts
creates different patterns of abnormalities. Segmental paternal UPD of 14q32 has
similar features as that of complete paternal UPD 14 (Kagami et al. 2008).
If a patient has inherited a recessive mutation from one parent and the segment
harbouring that mutation is homozygous due to UPD, the patient will present with
the disease. This is referred to as reduction to homozygosity. Several reports of
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FIGURE 5. MECHANISMS OF UPD FORMATION. Multicoloured chromosomes represent
recombination events. Red and purple chromosomes represent a heterodisomic pair,
whereas two red chromosomes represent an isodisomic pair.
1. Monosomic rescue in mitosis – a monosomic gamete is fertilized by a nullisomic gamete
and the single chromosome is duplicated during mitosis (isodisomic UPD).
2. Mitotic error and rescue:
a) non-disjunction with duplication (isodisomic UPD).
b) recombination or gene conversion (segmental isodisomic UPD).
3. Trisomic rescue in meiosis – a monosomic gamete is fertilized by a disomic gamete; one
chromosome is lost due to non-disjunction in meiosis resulting in either a) heterodisomic
UPD or b) isodisomic UPD.
4. Gamete complementation in meiosis – a disomic gamete is fertilized by a nullisomic
gamete (heterodisomic UPD).
reduction to homozygosity for a recessive trait inherited from one heterozygous
parent due to UPD have been published (Schollen et al. 2005, Malvagia et al. 2007,
Turner et al. 2007). There are some 26 reported cases of a pathogenic segmental
UPD and a normal karyotype, and in almost half of these the associated pathogenic
mechanism is reduction to homozygosity (Kotzot 2008).
UPDs were previously studied by screening polymorphic microsatellite markers of
DNA. This was a laborious method only suitable for targeted analysis of the patient
if he/she had specific clinical features justifying such an analysis. Today, the SNP
arrays provide an easier method of screening the whole genome for UPDs. All UPD
cases are collected on an online database run by the Institute of Human Genetics,
Jena, Germany (http://www.med.uni-jena.de/fish/sSMC/00START-UPD.htm).
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3.1.3 HIST ONE M OD IFI CATION
In the nucleus, DNA is wrapped around histone proteins in order to maintain the
dense structure characteristic of chromosomes. The N-terminal regions (tails) of
histones protrude through the chromatin and are able to interact with other
proteins. There are several different mechanisms contributing to numerous ways
that the histone tails can be modified such as methylation, acetylation,
phosphorylation, ubiqitination, ADP ribosylation, and SUMOylation. These
modifications have an effect on chromatin structure and may regulate the access of,
for instance, transcriptional proteins to genes by adopting an open or closed
heterochromatin structure (reviewed by Kouzarides 2007, Urdinguio et al. 2009)
Histone modifications can be studied by using antibodies in chromatin
immunoprecipitation and array analysis (ChIP on CHIP) or by mass spectrometry. A
problem in analysing histone modifications is that they rapidly change, making it
difficult to get a complete picture under set conditions (Kouzarides 2007, Tycko
2010).
3.1.4 SMAL L NON-COD ING RNA
Small non-coding RNAs are found in an abundance in eukaryotic cells, where they
regulate diverse functions such as chromosome architecture and growth control.
There are three major classes: miRNA, small interfering RNA (siRNA), and piwi-
interacting RNA (piRNA), all of which have important roles in controlling gene
expression (reviewed by Chang et al. 2009).
MiRNAs are found in abundance in our genome, and several hundred have already
been described. MiRNAs are double-stranded molecules that inhibit gene
translation in the cell cytoplasm by binding to the ribosomal complex with the help
of the Ago subclass of Argonaut proteins (Aravin et al. 2007). One miRNA may target
hundreds of different genes, and one gene may be regulated by several miRNAs in a
complex manner.
SiRNAs are the least understood of all the small RNA molecules. These are double-
stranded molecules that, as the name suggests, interfere with gene expression, also
by way of the Ago subclass of Argonaut proteins (Aravin et al. 2007).
PiRNAs are expected to be the most abundant of all non-coding RNAs. PiRNAs are
single-stranded molecules that interact with Piwi proteins, another subclass of
Argonaut proteins. PiRNAs are suggested to have an important role in silencing
transposons during development (Aravin et al. 2007).
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3.2 ENVIRONMENTAL FACTORS
Environmental factors account for approximately 6-7% of all DDs (Winter 1996).
So-called teratogenic agents are harmful to the foetus and may disturb
development also in the absence of genetic factors. Teratogenic agents are
generally thought to affect single genes or proteins in developmental pathways
since some teratogens and monogenic mutations cause the same or similar disease.
Human teratogens are categorized as drugs, maternal conditions, intrauterine
infections, heavy metal, radiation, procedures during pregnancy, and other (Holmes
2011).3.3 UNKNOWN FACTORS
Around 40-50% of patients with a DD have an unknown aetiology, i.e. idiopathic DD
(Leonard and Wen 2002). This group of patients indicates the need for new
technologies to improve diagnosis. Idiopathic DDs may be caused by genetic,
epigenetic, or environmental factors or by a combination of all of these. Most likely
the cause is genetic, and new technologies are anticipated to establish a genetic
diagnosis for most of these patients.
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4. GENETIC VARIATION IN THE HUMAN GENOME
The human genome sequence is 99.5% identical between humans, and 0.5%
accounts for the normal variation (Roberts et al. 2010, Figure 6). Several studies
during recent years have shown the abundance of genetic variation in the human
genome, varying from large chromosome anomalies to single-nucleotide changes.
These changes in copy number range in size from kilobases to megabases (Iafrate et
al. 2004, Sebat et al. 2004, Sharp et al. 2005, Conrad et al. 2006), are present in
several individuals of a population, and are mostly benign.
FIGURE 6. GENETIC VARIATION SHOWN HERE IN A COLOUR PATTERN. Similar colours represent
similar genetic variations in different populations, indicating a common ancestry. Picture
reprinted courtesy of Dr. Noah Rosenberg and Martin Soaves / University of Michigan.
A structural variation is a change involving a DNA sequence >1 Kb in size. These may
be balanced (e.g. inversions or translocations) in that they do not alter the copy
number of the genome. They may also be unbalanced and are then referred to as
CNVs. Both of these variations require a breakage in the DNA phosphodiester
backbone (Stankiewicz and Lupski 2010).
A CNV can further be defined as a DNA segment ranging in size from 1 Kb to several
megabases, present in a variable copy number between two genomes of one
species. These include deletions, duplications, and unbalanced insertions and
translocations ( Redon et al. 2006, Stankiewicz and Lupski 2010). Some CNVs are
pathogenic, but most are benign and referred to as copy number polymorphisms
(CNPs).
CNVs can be sporadic or inherited. The larger the CNV, the more likely it is to be
pathogenic, as it will probably involve several genes, some of which may be
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haploinsufficient. Several attempts have been made to catalogue CNVs in public
databases such as the Toronto Database of Genomic Variants (DGV), DECIPHER, and
the European Cytogeneticists’ Association Register of Unbalanced Chromosome
Aberrations (ECARUCA).
The rate of CNV formation is 100 to 10 000 times higher than that of nucleotide
substitutions (i.e. mutations) per locus or nucleotide, per generation (Zhang et al.
2009). This indicates that CNV formation may be more common than single
mutations. This also suggests that many clinically important CNVs are yet to be
discovered.
SNPs are naturally occurring single-base variants of the genome, where one base
differs between individuals at certain sequence locations. An estimated 10 million
SNPs are present in the human genome (Kruglyak and Nickerson 2001). SNP variants
are considered one of the driving forces of evolution.
4.1 THE INTERNATIONAL HAPMAP CONSORTIUM
A joint effort by the Human Genome Project, the SNP Consortium, and the
International HapMap Project has been to identify common variants, both SNPs and
CNVs, in samples from individuals of different populations. Data suggest that most
non-African populations have several similarities to African populations, whereas
there are low-frequency variants that set all populations, especially non-Africans,
apart (International HapMap 3 Consortium 2010).
The HapMap project has made available array data from a large set of healthy
individuals. High-resolution mapping of this data reveals that the median size of
CNPs is 2.9 Kb, and more than 95% are less than 100 Kb (Conrad et al. 2010).
In 2011, a high-resolution SNP study of 87 healthy Swedish individuals showed, on
average, 170 homozygous regions >500 Kb and 32 homozygous regions >1 Mb per
individual. This indicates that approximately 4.9% of the genome is homozygous in
Swedish individuals (Teo et al. 2011).
Since some variations are specific for certain populations, it may very well be, seeing
as the Finnish population has been isolated and is based on only a few founders (the
founder effect), that some variations are unique in Finns. Once mapping information
of the Finnish genome becomes publicly available, it will be valuable for classifying
detected chromosomal variations as either benign or pathogenic.
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4.2 MECHANISMS OF CNV FORMATION
The precision of CNV breakpoints between different samples is immaculately
precise, with a median estimated error of ~60 bp (Conrad et al. 2010). This indicates
that common mechanisms act on specific locations, such as those described below.
4.2.1 LOW-COPY REPEATS
Low-copy repeats (LCRs), also called segmental duplications (SDs), are regions of
highly homologous, duplicated sequences in the genome that range in size from 1 to
400 Kb. They have, by definition, a sequence identity of more than 90% and occur at
more than one site of the genome. LCRs usually reside near the centromeres or
telomeres of the chromosome (Eichler et al. 1999).
LCRs provide the basis for various chromosomal rearrangements (Sharp et al. 2005).
In fact, LCRs have been implicated in >25 recurrent genomic disorders (Stankiewicz
and Lupski 2002). In one study, 130 areas of so-called rearrangement hotspots, i.e.
genomic locations surrounded by LCRs, were analysed on an array, and the results
indicated a 4- to 5-fold enrichment of CNPs within these regions (Sharp et al. 2005).
In a follow-up of this study, the array was applied to screen 290 patients with
idiopathic DDs, and five new microdeletion syndromes were defined (Sharp et al.
2006).
4.2.2 NON-A LL ELIC H OMOL OG OUS R EC OM BI NA TION
NAHR is a mechanism considered responsible for the majority of common-sized
recurrent rearrangements. It is based on the misalignment and cross-over of non-
allelic DNA segments, such as LCRs, resulting in deletions, duplications (Figure 7),
and inversions (Figure 8a). NAHR may occur if the LCRs have >97% sequence identity
and are located <10 Mb apart. If the LCRs are on the same chromosome and in
direct orientation, NAHR mediates a duplication or deletion of the intervening DNA
segment. If the repeat is inverted, NAHR mediates inversion of the DNA segment
that the repeats are flanking. If the recombination occurs between repeats on
different chromosomes, it may mediate translocations ( Lupski 1998, Stankiewicz
and Lupski 2002).
Other repetitive sequences that can cause this form of recombination include
retrotransposable L1 elements, Alu repeats, and matching pseudogenes (reviewed
by Zhang et al. 2009). If NAHR occurs during meiosis, it can cause a congenital
benign polymorphism or a de novo or inherited genomic disorder (Turner et al.
2008). NAHR in mitosis leads to mosaicism, with some normal cells and some with a
copy number or structural variation.
Some 33 new syndromes have been described as a consequence of recurrent
rearrangements at one of 21 known recombination hotspot regions of the genome.
These hotspots undergo rearrangement more frequently than other genomic areas
due to flanking LCRs (Mefford and Eichler 2009).
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Figure 7. NAHR may lead to duplications or deletions by misalignment and crossing-over
of homologous segments.
4.2.3 NON-H OM OL OG OUS END JOI NI NG
Non-homologous End Joining (NHEJ) is a mechanism normally responsible for the
repair of double-strand breaks in the DNA. Malfunction of the repair mechanism
may cause loss or gain of nucleotides at the end junction of the DNA strands, and
this can cause imbalance. NHEJ mainly causes non-recurrent rearrangements and
monogenic disorders (Gu et al. 2008).
4.2.4 FOR K STA LL ING AND TEM PLAT E S WITCH ING
Fork Stalling and Template Switching (FoSTeS) is a mechanism based on errors
during DNA replication. As the replication fork stalls, the lagging strand disengages
and binds to another replication fork close-by and synthesis continues there. This
can happen several times, causing aberrations at several locations. FoSTeS seems to
be the main mechanism causing complex deletion and duplication rearrangements.
These are non-recurrent rearrangements that differ in size and breakpoints
between individuals (Lee et al. 2007).
4.2.5 L1 RETR OTRA NS POS ITI ON
Around 17% of the genome consists of mostly inactive, long, interspersed nuclear
element-1 elements (LINE1 or L1). These are transposable elements that are active
during embryogenesis. L1s encode an RNA-binding protein as well as an enzyme
with endonuclease and reverse transcriptase activity (Kano et al. 2009). L1
transcripts integrate into euchromatic (gene-poor) regions by a copy and paste
process driven by the reverse transcriptase. L1 retrotransposons may cause disease
in a number of ways, i.e. by promoting NAHR, inserting L1 transcripts into genes,
and inserting other elements into genes (Ostertag and Kazazian 2001).
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4.2.6 INV ERS IONS P REDISP OSI NG T O STRUCT URAL
REAR RA NG EM ENT
The genome consists of polymorphic inversions scattered at various loci. These
inversions predispose to further rearrangement by two suggested mechanisms. In
regions with two identical repetitive sequences lying in opposite directions to each
other, an inversion of one sequence will render both in the same orientation. This
causes a problem during meiosis, as NAHR between the directly oriented repeats
may lead to deletion or duplication of the intervening material (Figure 8a). The
inversion can prevent synapsis between chromosomal segments in meiosis due to
non-homology, rendering the segment unstable and free to undergo further
rearrangement (Figure 8b) (Sharp 2009).
FIGURE 8. MECHANISM OF INVERSION. a) An inversion in one chromosome, rendering two
segments in the same orientation, followed by NAHR between directly oriented repeats can
create imbalance. b) An inversion can make synapsis impossible in meiosis. Reprinted from
Human Mutation, Vol. 30 (2), Sharp A., Emerging themes and new challenges in defining
the role of structural variation in human disease, pp. 135-144, Copyright (2008), with
permission from John Wiley and Sons.
Some polymorphic inversions may be particularly common in certain populations, as
is the case with the 900 Kb polymorphic inversion predisposing to the 17q21.31
deletion syndrome. This region of chromosome 17 has two haplotypes, H1 and H2.
H2 is the inverted form and is found in 20% of Europeans, whereas it is almost
absent in African and Asian populations. A healthy parent carrying the H2 haplotype
with the inversion may transmit the chromosome in an unbalanced state to their
child by means of uneven crossing-over or NAHR, causing the 17q21.31
microdeletion syndrome (Rao et al. 2010).
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5. DIAGNOSTIC METHODS
The prevailing cause of DDs is chromosomal abnormalities. In this section, the
available diagnostic methods for analysis of chromosomal defects and their
estimated diagnostic yield are reviewed. The yield of a method is an estimation of
how many patients receive a diagnosis using the method. As diagnostic methods
continuously evolve, it is important to keep track of the benefits of various
techniques. After thorough testing, often by research groups, new technology can
be implemented into routine diagnostic laboratories. Such has been the case with
the array analysis method, which has gradually gained ground and is now used as
the first line of testing for DDs in many diagnostic laboratories.
5.1 CYTOGENETIC AND MOLECULAR CYTOGENETICMETHODS
Introduced in the 1950s by Caspersson et al., standard chromosome analysis by
karyotyping is the simultaneous analysis of all chromosomes of a cell, by cell cycle
arrest in metaphase, spreading the chromosomes on a glass slide, staining them,
and analysing them under a light microscope (Caspersson et al. 1968). Metaphase
chromosomes receive an enzymatic trypsin treatment that affects the proteins of
the chromatin. Subsequent giemsa colouring, in which the colour reacts with the
DNA/protein complex, visualizes a banding pattern characteristic for each
chromosome. Gene-rich areas receive a light pattern and gene-poor areas a dark
pattern, creating the typical G-banding pattern. The bands of a chromosome are
reported according to an International System for Human Cytogenetic
Nomenclature (ISCN). The short arm of a chromosome is termed p and the long arm
q. Further, each band has its own designated number, e.g. 13p11.2
With a resolution of 500 bands, it is possible to detect chromosomal aberrations as
small as 5-10 Mb. Aberrations of this size will almost certainly cause developmental
abnormalities during embryogenesis. The reported diagnostic yield of this method
varies, but has been estimated to be around 11-20% in patients with a DD ( Battaglia
et al. 1999, van Karnebeek et al. 2005) and around 4% in patients with
developmental delay (Shevell et al. 2003). The yield of karyotyping in patients with
an idiopathic DD is 4-5% (Hochstenbach et al. 2009).
At the end of the 20th century, several syndromes (e.g. Wolf-Hirshhorn, Cri du Chat,
and Williams.) were established with the help of the FISH method, which was first
described in 1982 by van Prooijen-Knegt et al. With this method, small deletions are
visualized. Targeting the chromosomal area of interest by hybridizing a fluorescently
labelled locus-specific probe to a metaphase or interphase chromosome spread and
visualizing the labelled chromosome under a fluorescent microscope enables
detection of aberrations. The size of the probe (~200 Kb) limits the detectable size
of the deletion. Small deletions, detectable by FISH, are termed microdeletions
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(Raymond and Tarpey 2006). Duplications are harder to detect, as interpretation is
dependent on the intensity of the fluorescent signal seen under the microscope.
The FISH-technique was further developed to only screen the subtelomeric areas of
the chromosomes for detection of deletions (Flint et al. 1995). Screening of
subtelomeric aberrations in patients with idiopathic DD has a yield of ~2.5% (Ravnan
et al. 2006).
Despite the valuable findings made by karyotyping and FISH over the years,
karyotyping provides an overview of the whole genome only at a low resolution and
FISH provides only targeted analysis at high resolution. These limitations have
turned attention towards molecular cytogenetic analysis, particularly in the form of
microarray analysis.
In 1992, a new method was described by Kallioniemi et al. that revolutionized
whole-genome studies. The method of comparative genomic hybridization
(CGH) enabled simultaneous comparison of a patient and reference genome by
staining chromosomes with separate fluorescent dyes and subsequently co-
hybridizing them onto a glass slide with fixed metaphase spreads (Kallioniemi
et al. 1992). This cytogenetic method enabled detection of copy number
variants at a 5- to 10-Mb resolution by comparing the fluorescent signal ratios
between patient and reference samples.
In the early 1990s the first microarray used for array CGH analysis was
developed by Fodor et al. at the Affymax Research Institute (Fodor et al. 1991).
The metaphase chromosomes were replaced on the glass slide by cloned DNA
fragments (100-200 Kb). The simultaneous sequencing of the human genome in
the Human Genome Project enabled detailed mapping of the cloned DNA
fragments to the genome. In 1991, Affymetrix, as part of Affymax, started
production of the first commercial microarrays.
As one of the first to publish using the microarray method, Pinkel et al.
concluded that array CGH was well suited for genotype-phenotype correlation
studies and would likely reveal many new CNVs (Pinkel et al. 1998). This turned
out to be true.
The first microarray platforms used to study DDs were based on BAC (bacterial
artificial chromosome) probes. The yield was around 10% (Vissers et al. 2003,
Shaw-Smith et al. 2004). At the beginning of the 21st century, oligonucleotide
probes were introduced as a replacement to the larger BAC clones.
Oligonucleotide probes are only 25-85 bp long, whereas BAC probes are
generally 100-200 Kb.
Array CGH has rapidly become the standard analysis method in most clinical
diagnostic laboratories. With its massively increased resolution relative to
conventional cytogenetic testing, it detects CNVs much better. Several studies have
shown the detection rate of this method to be 10-20% of patients with DD and a
normal karyotype (Vissers et al. 2003, Shaw-Smith et al. 2004, de Vries et al. 2005a,
Schoumans et al. 2005, Menten et al. 2006, Rosenberg et al. 2006, Aradhya et al.
2007, Fan et al. 2007, Shen et al. 2007, Lybaek et al. 2008).
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5.2 MOLECULAR DNA METHODS
Aberrations undetectable by cytogenetic analysis require high-resolution methods
to analyse the genome at gene level.
Polymerase chain reaction (PCR) is a basic DNA amplification method widely used
in genetic laboratories. The DNA sequence of interest is targeted by sequence-
specific primers and subsequently amplified using a polymerase enzyme. The end
product is visualized on an agarose gel or the quantity of the product is measured
using real-time systems. PCR, thus, enables the detection of copy number
(quantitative PCR, qPCR) as well as amplification of a target DNA sequence for
further studies. As such, PCR is not suitable for screening purposes, but is valuable
for validating results and for targeted analysis. As a variation of standard PCR,
multiplex ligation-dependent probe amplificaction (MLPA) was developed for
targeted quantitative measurement of several genes simultaneously. By using a
panel of probes targeting the genes of interest (e.g. all known dyslexia genes), the
method enables rapid testing of a certain disease (Schouten et al. 2002). Screening
by MLPA of the subtelomeric chromosomal areas in patients with idiopathic DD has
a yield of ~6% (Koolen et al. 2004).
SNP markers have for some time been used for genome-wide association studies to
pinpoint disease genes associated with polygenic diseases (Manolio et al. 2009,
Roberts et al. 2010), as well as for population studies (Salmela et al. 2008). On SNP
arrays, the probes are designed to target single-nucleotide variants. A SNP array is
able to measure copy number variants as well as the allele ratio of a genome. This
enables detection of regions with allelic homozygosity such as haplotype blocks, loss
of heterozygosity (LOH), or UPD. SNP arrays have also been used in several
screening studies to detect CNVs in DD patients (Friedman et al. 2006, Baross et al.
2007, Wagenstaller et al. 2007, Bernardini et al. 2010, Mannik et al. 2010). A recent
advancement in SNP array technique has been the addition of copy number probes,
in addition to SNP probes. Copy number probes enable more comprehensive copy
number profiling, while the SNP probes gives information of sequence homology
(e.g. UPD). The diagnostic yield of SNP arrays is similar to that of CGH arrays, 10-
20%, depending on the resolution of the array platform used.
Sequencing is the ultimate high-resolution method for detecting CNVs by reading
the bp sequence of the DNA strand. First developed in the early 1970s by Frederick
Sanger, the Sanger sequencing method has been widely applied in various fields of
research (Sanger and Coulson 1975). Several improvements have since been made
and nowadays sequencing of the whole genome is possible by using highly
automated sequencing instruments, referred to as next-generation sequencing
(NGS). Besides detecting single-nucleotide changes, the paired-end sequencing
method is used to identify balanced structural variations such as translocations that
are otherwise undetectable by array CGH. Problems with NGS arise when the
amount of data exceeds our interpretation capacity
The expectations for whole-genome sequencing are high, and once data
management and expenses become manageable, this method will likely be part of
routine diagnostic testing. An optimistic estimation of the yield of whole-exome
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sequencing in DDs is up to 80% (Vissers et al. 2010). However, this is based on one
study consisting of only 10 patients.
5.3 OTHER METHODS
Understanding the effect of copy-number changes requires functional studies of the
genome. Oligonucleotide arrays can be used to measure gene expression. The
amount of translated gene sequence, in the form of messenger RNA (mRNA)
present in a sample, can be studied by microarray expression analysis. In short, the
RNA fraction is converted to cDNA and hybridized to the microarray (Schena et al.
1995). This method gives an estimate of global gene expression levels. Expression
analysis can be used to see the effect that structural changes, such as deletions or
duplications, have on gene expression.
Studying the role of miRNA regulation has become increasingly popular, mostly in
evaluation of cancer specimens. MiRNA microarrays enable global detection of
miRNA expression, by extraction of size-fractionated RNA, conversion to cDNA, and
subsequent hybridization onto the array (Barad et al. 2004).
Methylation arrays enable detection of methylated regions.The DNA sample is first
treated with sodium bisulfate, which deaminates unmethylated cytosine to uracil,
leaving methylated cytosine intact. After targeted PCR amplification and
purification, the sample is hybridized onto a microarray (reviewed by Shi et al.
2003).
As DDs are constitutional disorders, deviations in gene or miRNA expression levels
during development are not necessarily measurable in children or adults. Moreover,
the expression pattern of genes and miRNA varies and is not necessarily the same in
all tissues. Thus, the above mentioned array methods are useful for investigating
disorders only when the study is restricted to a certain tissue or developmental
stage (Chen et al. 2010).
As a source for diagnostic analysis, routine metabolic studies have a low diagnostic
yield of around 1% (van Karnebeek et al. 2005, Shevell et al. 2003), but are essential
when a metabolic disease is suspected.
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6. ASSESSING THE PATHOGENIC SIGNIFICANCE
OF CNVS
Over the years, as molecular analysis methods have evolved, we are able to perform
increasingly detailed screening of the human genome. The problem today concerns
the interpretation of results, rather than the identification of aberrations. CNVs may
affect the expression of genes in several different ways, creating phenotypic
variation and adaptation. CNVs may cause disease or confer risks to complex
disease traits. The most common CNVs have been suggested to involve genes of the
extracellular pathways and as such are of lesser importance than those involving
genes of the intracellular pathway (Conrad et al. 2010). However, distinguishing
pathogenic CNVs from polymorphic CNVs is challenging.
6.1 GENOMIC EFFECT
The most common ways that a chromosomal aberration conveys a phenotypic
effect are gene dosage, disruption, and position.
6.1.1 GENE DOSA G E
A deletion or duplication of a dosage-sensitive gene can alter gene expression
levels, causing either under- or overexpression of a protein. Genes that need to be
expressed at a precise level and do not have the correct effect when
underexpressed are termed haploinsufficient. The gene dosage effect is perhaps the
most common mechanism whereby genomic rearrangements convey phenotypes.
One suggested way of distinguishing pathogenic CNVs from polymorphic CNVs is to
assume that large aberrations (>2 Mb) are likely pathogenic since they can involve
several dosage-sensitive genes, which is presumably harmful (de Vries et al. 2005b).
The DECIPHER database contains information on which genes are likely to be
dosage-sensitive (Huang et al. 2010).
6.1.2 GENE DISR UPTI ON
The simplest way of gene disruption is direct disruption of a gene by deletion.
Balanced inversions and translocations may also be disruptive if the breakpoint of
the rearrangement occurs within a gene.
In one study of a patient with microcephaly, congenital bilateral falciform retinal
folds, nystagmus, and ID, qPCR analysis showed haploinsufficiency of CDK19, caused
by a disrupting pericentric inversion (6)(p11.1q21), but a normal copy number. The
orthologous gene (cdk8) in Drosophila plays an important role in eye development,
and thus, it is hypothesized that haploinsufficiency of CDK19 in this patient is
responsible for the eye defects (Mukhopadhyay et al. 2010).
A more complex pattern of disruption comes from the disturbance of control
elements. Functional expression of a gene requires the co-operation of promoters,
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regulatory elements, and cis-acting distant elements (enhancers), all usually located
within 1 Mb in either direction of the gene. Any disturbance of the interaction
between the promoter and enhancers or other regulatory elements may disrupt
transcriptional control (Kleinjan and van Heyningen 2005). Chromosomal
aberrations may affect the function of these control mechanisms, thus affecting the
expression of the gene.
Not all genes require enhancers or regulatory elements, such as housekeeping
genes, which are ubiquitously expressed in most cells. Tissue-specific genes,
responsible for function and regulation of differentiated cells, are regulated by one
or several enhancers. Genes regulating development are strictly controlled by
several enhancers and regulatory elements, so as to function only at specific
developmental stages (Kleinjan and van Heyningen 2005).
6.1.3 POSIT I ON EFFEC T
Having similar consequences as a disruption, chromosomal rearrangements can
create a position effect whereby a gene by translocation is put under the control of
a foreign regulatory element, or is separated from its own control element.
De novo balanced chromosomal rearrangements are found in 0.0009% of prenatal
screenings (Giardino et al. 2009). DDs are twice as frequent in newborns with de
novo balanced chromosomal rearrangements, as in the general population (Chen et
al. 2010). In most of these cases, the phenotypic effect is conveyed by disruption,
and less frequently by position effect. However, Yue et al (2007) described a boy
with skeletal malformations and a de novo translocation (12;17)(p13.3;q21.3),
detected by karyotyping and further characterized by FISH and expression studies.
Their study showed that the breakpoint at chromosome 17 lies in close proximity to
the HOXB gene cluster, and the authors concluded that the phenotype of the
patient is consistent with loss of function of the HOXB genes, indicating that the
translocation has separated the gene cluster from their regulatory elements.
6.2 PENETRANCE
The standard praxis may have been to assume that if a detected aberration is
inherited from a phenotypically normal parent it is less likely to be pathogenic.
There are exceptions to this rule; in certain diseases, the majority of patients inherit
the aberration from their phenotypically normal parent, showing variable
penetrance between parent and offspring (Sharp 2009). Several examples in the
literature reveal that certain syndromes have variable penetrance. For example, the
200- to 500-Kb deletion of 1q21.1, associated with Thrombocytopenia with Absent
Radius (TAR) syndrome, is in 75% of the cases inherited from a phenotypically
normal parent (Klopocki et al. 2007). The cause of variable penetrance is suggested
to be imprinting, unmasking of a recessive mutation, genomic polymorphisms, or
the two-hit hypothesis.
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6.2.1 IMP RI NTI NG
The mechanism of imprinting is well known for some 100 loci. Some allelic genes of
a chromosome are expressed in a parent-specific manner, with one allele silenced
by methylation (see Sections 3.1.1 and 3.1.2). In general, imprinting is rarely a cause
of disease, but can be a source of variable penetrance. For certain diseases, there is
a clear bias in imprinting towards one parental chromosome.
6.2.2 UNMASKI NG OF REC ESSI V E MUTATI ON
A microdeletion may cause the unmasking of a recessive mutation on the intact
allele, thus enabling its expression (or lack thereof) in a homozygotic manner (Sharp
2009). This may be the cause of variable penetrance in certain microdeletion
syndromes. Some patients have a normal intact haplotype, while others express a
recessive disorder in addition to the microdeletion phenotype.
The Wolf-Hirschhorn syndrome (WHS) is associated with a highly variable
phenotype (e.g. ID, growth delay, epilepsy, dysmorphism). In 80% of affected
patients, WHS is caused by a hemizygous 4p16.3 deletion, and in 20% by a
translocation between chromosomes 4 and 8. One patient with WHS as well as
features of the recessive Wolfram syndrome (WFS) was shown to have a 8.3 Mb
deletion of 4p, including the WFS gene WFS1. However, a hemizygous deletion
alone could not cause WFS; further studies revealed that the intact allele of WFS1
had a point mutation. The deletion thus caused unmasking of the mutation,
explaining the uncommon phenotype of the patient (Flipsen-ten Berg et al. 2007).
6.2.3 GENOMIC POLYM OR PHISMS
A polymorphism in the intact allele in addition to a microdeletion may influence the
outcome of a phenotype. In patients with velo-cardio-facial syndrome (VCFS) caused
by the 22q11.21 deletion, the presence of two polymorphic variants within the
intact COMT, Val158Met, has been the subject of several studies (reviewed by Furniss
et al. 2011). The two Val158Met polymorphic variants within COMT affect the
functional activity of the encoded enzyme, which is an important inactivator of
catecholamine neurotransmitters (Lachman et al. 1996). One study suggested that
the Met158 polymorphism in the single intact allele of COMT is associated with a
higher prevalence of schizophrenia in deletion carriers (Bearden et al. 2004). The
Val158 variant cause increased activity, while the Met158 variant causes decreased
activity (Graf et al. 2001). The outcome of schizophrenia in association with VCFS is
proposed to depend on the polymorphic variant left after the deletion.
6.2.4 TH E TWO-H IT M OD EL
The proposed two-hit model suggests that variation in severity of a syndrome is
caused by a second chromosomal aberration in patients with a more severe
phenotype, in addition to the known causative aberration. This was exemplified in
the meta-analysis study by Girirajan et al. (2010), where 16p12.1 microdeletions
were identified with a 1:15 000 prevalence, in a large cohort (n=11 873) of
individuals with ID, autism, and schizophrenia. The clinical presentation of the
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16p12.1 microdeletion in patients was variable, so the presence of other
chromosomal abnormalities was investigated. The authors discovered that 6% of
patients with a more variable or severe phenotype had an additional aberration
(>500 Kb) at another chromosomal location, as opposed to the other 16p12.1
patients. This two-hit model was further supported by the fact that in some of these
patients the second hit was inherited from a parent who did not carry the
microdeletion 16p12.1, but who presented with some milder neurological defects.
Population studies have also shown that phenotypically normal individuals can have
large CNVs that would generally be associated with a disease. If variable penetrance
is common, some CNVs have likely been falsely labelled as benign. This also
indicates that microdeletion/-duplication syndromes may be associated with highly
variable phenotypes. In addition, the rearrangements causing genomic disorders
may be more common than previously estimated.
6.3 INFORMATIVE DATABASES
Due to the abundance of CNVs in the human genome, it is sometimes very difficult
to discriminate pathogenic CNVs from benign CNVs. Public databases, such as the
DGV, are useful for ruling out common CNPs. A problem with this database is,
however, that it consists of data from different sources; researchers have used
different platforms and settings to obtain their results, and thus the content of the
database is very heterogenous. Care should be taken not to over-emphasize the
reports in the database since many changes are overestimated (Sharp 2009). As
shown by a fine-scale study of CNVs reported in the DGV, the extent of 88% of the
changes was overestimated. In fact, 76% of the reported changes in DGV were
actually 50% smaller than reported (Perry et al. 2008). Some variations previously
labelled as benign may in fact be pathogenic. Evaluation of pathogenicity is very
much dependent upon the person conducting the analysis, and thus it is important
to store information about all detected aberrations, enabling reassessment of old
results in light of new research. Some CNPs may also be specific for certain
populations, as different populations exhibit their own, specific set of variations,
and therefore, a global database of variations is not entirely unbiased.
Aberrations that have been previously associated with a clinical phenotype similar
to that of the patient should be considered significant. At least two online
databases, DECIPHER (Huang et al. 2010, https://decipher.sanger.ac.uk/) and
ECARUCA (http://umcecaruca01.extern.umcn.nl:8080/ecaruca/ecaruca.jsp), store
genotype and phenotype data of patients with idiopathic DD. These databases
enable clinical characterization of new findings.
DECIPHER and Endeavour (Aerts et al. 2006) databases are also useful in prioritizing
candidate genes. These databases use information from different sources that, in
combination, allow prediction of the importance and disease association of a gene.
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6.3.1 TH E INT ER NATI ONAL STA NDARDS FOR CYTOGENOMI C
ARRAYS CONS ORT IUM
The International Standards for Cytogenomic Arrays Consortium (ISCA)
(www.iscaconsortium.org) has published a consensus statement recommending
microarrays as a first-tier diagnostic test for patients with DDs. They have also
published guidelines on how to assess CNVs as either pathogenic or benign. These
are presented in Table 2 (Miller et al.2010).
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Table 2. Assessment of pathogenicity of a CNV a
Primary criteria Indicates CNV is probably
Pathogenic Benign
1 a. Identical CNV inherited from a healthy parent b x
b. Expanded or altered CNV inherited from a parent x
c. Identical CNV inherited from an affected parent x
2 a. Similar to a CNV in a healthy relative x
b. Similar to a CNV in an affected relative x
3 CNV is completely contained within genomic
imbalance defined by a high-resolution technology in
a CNV database of healthy individuals
x
4 CNV overlaps a genomic imbalance defined by a
high-resolution technology in a CNV database for
patients with ID/DD, ASD, or MCA
x
5 CNV overlaps genomic co-ordinates for a known
genomic imbalance syndrome (i.e., previously
published or well-recognized deletion or duplication
syndrome)
x
6 CNV contains morbid OMIM genes c x
7 a. CNV is gene-rich x
b. CNV is gene-poor x
General Findings d
1 a. CNV is a deletion x
b. CNV is a homozygous deletion x
2 a. CNV is a duplication (no known dosage) x
b. CNV is an amplification (greater than 1 copy gain) x
3 CNV is devoid of known regulatory element x
a) Single copy number change.
b) An inherited deletion from an unaffected parent could harbour an OMIM morbid gene that is recessive and could be
pathogenic in conjunction with a point mutation on the trans allele inherited from the other parent.
c) CNV should produce the same type of mutation known to cause the OMIM disease (e.g. a heterozygous deletion can
cause an OMIM disease that is usually caused by a heterozygous inactivating mutation) and the phenotype produced
should be that expected for the OMIM disease.
d) Exceptions to each case have been seen.
Modified and reprinted from The American Journal of Human Genetics, Vol, 86(5), Miller et al. (2010), with permission
from Elsevier.
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AIMS OF THE STUDY
1. To analyse 150 patients using the array CGH method to determine the
percentage of pathogenic CNVs detectable using this method.
2. To describe new microdeletion and/or amplification syndromes through
observed chromosomal aberrations and to characterize target genes and
their function, thereby shedding light on the pathogenesis of the disorder.
3. To analyse patients with normal array CGH results with a higher resolution
SNP array to see whether additional pathogenic small CNVs are detected
that were missed by array CGH, and to document the occurrence of
uniparental disomies in the genome and determine whether these could be
pathogenic.
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MATERIALS AND METHODS
7. PATIENTS AND SAMPLES
7.1 ETHICAL PERMISSIONS
Ethical permission for this research project was granted by the Ethics Review Board
for Paediatric and Psychiatric Diseases in the Helsinki and Uusimaa Hospital District
(consent nos. 23/E7/2007 and 24/13/03/03/2009). Informed consent was obtained
from participating families in Studies II-IV. Study I patients had previously been
analysed for diagnostic purposes, after referral by their clinician. The results for
Study I were subsequently retrieved from a database in collaboration with each of
the patients’ clinicians. Patients were informed of study results by their clinicians.
7.2 SAMPLE COLLECTION AND MANAGEMENT
Study I was based on 150 patients (Table 3) with idiopathic ID and/or dysmorphic
features and/or malformations. Patient data were collected from the registry of
HUSLAB’s Laboratory of Molecular Pathology. All 150 patients had a normal
karyotype by G-banding (300-550 band level) and had subsequently been studied by
array CGH for diagnostic purposes. The earliest cases were studied using a 44K
platform, and the more recent ones using a 244K platform. Patients for the study
were selected in a consecutive manner over the period from 2005 to 2008. Patients
were aged a few months to 25 years at the time of diagnosis by array CGH. Clinical
data of each patient were restricted to information available on the referral form.
When needed, the clinicians treating the patients were consulted.
In Study II, a family consisting of both parents, three children, and the paternal
grandparents was analysed to determine the source of variable penetrance of a
detected deletion (Table 3). Blood samples were collected from each participant.
In Study III , a family from Study I (patients 9, 10, and 11) was further investigated in
an effort to establish the pathogenic mechanism of a detected duplication (Table 3).
Blood and urine samples were collected from each patient.
In Study IV, 35 patients with normal karyotype and array CGH results were selected
for further analysis by the high-resolution SNP 6.0 array (Table 3). Blood samples
were collected from all patients and their parents.
All samples were designated a research number. Patient information and samples
were given the same coded number to keep patient data confidential. For each
project, patients were re-numbered for optimal clarity of the manuscripts. In all
studies, DNA was extracted using a standard non-enzymatic salting out method
(Lahiri and Nurnberger 1991). DNA purity and concentrations were measured using
the Nanodrop Spectrophotometer (Thermo Fisher Scientific Inc., DE, USA).
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Table 3. Summary of studies I to IV
Study Study I Study II Study III Study IV
Number of patients 150 3 (father + 2
children)
3 (mother + 2
children)
35
Number of parents
analysed
29 2 + paternal
grandparents +
healthy brother
1 (mother, father
unavailable)
19
Patients with
pathogenic
aberrations
28 3 3 0
Primary analysis
method
Array CGH Array CGH Array CGH SNP array
Other analysis MLPA, q-PCR,
karyotyping
Karyotyping, SNP
array, FISH
Karyotyping, SNP
array, MLPA,
sequencing, enzyme
and metabolite
studies
Microsatellite
marker analysis
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8. MICROARRAY ANALYSIS
8.1 ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (I, II,III)
Array CGH analysis, using Agilent Technology’s 44K and 244K oligonucleotide
microarrays (Agilent Technologies, Santa Clara, CA, USA), was initially performed at
HUSLAB’s Laboratory of Molecular Pathology as a diagnostic service. Some arrays
were re-hybridized to a 244K array platform, due to interpretation difficulties. All
samples were re-analysed regardless of previous results, and copy number changes
were re-evaluated according to current norms.
Array CGH was performed (Figure 9) according to manufacturer protocols (Agilent
Technologies, Santa Clara, CA, USA). As a reference, DNA extracted from the pooled
blood of four healthy males or females was used. In short, DNA concentrations were
measured and matching concentrations of patient and reference DNA were
prepared (1.5 µg/20.2 µl). Quality of the starting material was checked on a 1.2%
Flash gel system (Lonza Group, Basel, Switzerland) to avoid the use of degraded
samples. Samples were digested using restriction enzymes Alu I and RsaI, cutting the
DNA into 200- to 400-bp strands. The success of the fragmentation was checked on
a gel. Samples were labelled with fluorescent Cy3 (reference) and Cy5 (patient) in an
Exo-Klenow polymerase-driven reaction. The labelled samples were cleaned of
excess labels and nucleotides, and the concentration of labelled DNA was measured
using the Nanodrop spectrophotometer. Patient and gender-matched reference
samples were combined and subsequently co-hybridized onto a glass slide covered
by oligonucleotide probes (44000 or 244000). During hybridization the labelled DNA
fragments compete for binding to the probes. After washing off unbound DNA, an
Agilent high-resolution microarray laser scanner (Agilent Technologies, Santa Clara,
CA, USA) read the different signal intensities of each label (Cy3 or Cy5) for each
probe on the array. Data from the scanned tif-image were extracted using the
Feature Extraction software V.9.5.3.1 (Agilent Technologies, Santa Clara, CA, USA)
and analysed using the CGH Analytics software V.3.5.14 (Agilent Technologies, Santa
Clara, CA, USA). During extraction the software creates a text-file with information
regarding the signal intensities of each probe and the mapping location of that
probe. The signal intensities are simultaneously converted into a log2-ratio, which is
central to the analysis of the results. The log2-ratio indicates the copy number state
of the particular genomic segment that the probe represents in the patient. Log2-
ratios of zero indicate a normal copy number of two, ratios of less than -0.5 indicate
loss of one copy, and ratios of less than -1 indicate loss of two copies. Ratios of over
0.5 indicate gain of one copy, and ratios of more than 1 indicate gain of two or more
copies.
Analysis settings were selected to detect aberrations using the ADM2-algorithm of
the CGH Analytics software and a 0.2 Mb window for calculating the average log2-
ratio. Results were filtered based on a minimum of four consecutive probes with a
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FIGURE 9. SCHEMATIC OVERVIEW
OF THE AGILENT ARRAY
LABORATORTY PROTOCOL.
Patient and reference DNA is
digested into 200-300bp
fragments. Quality of the
fragmentation is checked on a
gel. Both fractions are labelled
with an individual fluorescent
label (Cy3 or Cy5). Samples are
purified to remove exess labels
and small DNA fragments. The
success of labelling is checked
by measuring the
concentration of Cy3 and Cy5.
Reference and patient samples
with an equivalent amount of
dye are co-hybridized onto the
array slide. Glasses are
hybridized in an oven for 40h
and unbound fragments are
then washed off. The glass
slides are immediately
scanned. Data are extracted
from the scanned image in the
Feature Extraction software.
This data can then be analyzed
by e.g. the Genomic
workbench software.
26.3.2009
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minimum log2-ratio of 0.4/-0.4. When the average log2-ratio in the 0.2Mb window
exceeds the parameters for loss or gain, the software marks that genomic area in a
shaded colour to make visual detection easier (Figure 10). If the results are of poor
quality, it is hard to detect any changes due to background noise, which causes a
wider overall spread of the representative log2-plot around the zero-line than is
acceptable. Poor quality DNA may cause such background noise, due to unspecific
binding of fragmented DNA to the probes, or to the area around the probes making
it difficult for the scanner to detect the signal peaks of individual probes.
FIGURE 10. RESULTS OF ARRAY CGH ANALYSIS. (A) depicts chromosome 9 as seen in the
Agilent CGH Analytics software. The shaded areas mark a deletion 9p23p22.2 to the left
and a duplication 9p21.3 to the right, in this case 7.75 Mb and 1.43 Mb, respectively. The
insert (B) depicts the zoomed view of the aberrated regions, where genes of the area are
made visible. This aberration was detected in patient 14 in Study I.
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8.2 SINGLE-NUCLEOTIDE POLYMORPHISM ARRAY (II, IV)
Small copy number changes and stretches of allelic homozygosity were
characterized by using the Affymetrix Genome-wide Human Single-Nucleotide
Polymorphism Array 6.0 (SNP 6.0 array).
The study was performed according to the manufacturer’s protocol (Affymetrix,
Santa Clara, CA, USA). In brief, 500 ng of patient DNA was separated into two
digestion reactions, one with NspI enzyme and the other with StyI enzyme, creating
4 bp overhangs on the DNA fragments. NspI and StyI adapters were ligated to the
fragments, and in the following step the adapters served as binding sites for the PCR
primer during amplification. After combination of the two reaction pools, clean-up
and quantitation followed using the Nanodrop Spectrophotometer. The sample was
then further fragmented into ~180 bp segments. After labelling of the sample with
biotin, it was hybridized onto the SNP array glass and hybridized for 16-18 hours.
During post-hybridization washes in a GeneChip fluidics station 450 (Affymetrix), the
bound DNA fragments were labelled by antibodies; Streptavidin R-Phycoerythrin
(SAPE) binding to biotin and a biotinylated anti-streptavidin monoclonal antibody
binding to SAPE; and scanned using a GeneChip scanner 3000 7G (Affymetrix).
Data from the scanned DAT image were extracted using the Genotyping Console
software V.3.0.2 and the Hidden-Markow model. As a reference set, 90 samples of
Caucasian individuals were used that had previously been analysed in the HapMap
project using the SNP 6.0 array. The extracted data were converted into a CEL file
that can be imported into the desired analysis programs, such as the Chromosome
Analysis Suite V.1.0 (Affymetrix).
Due to the vast amount of data generated by the array, the calling criteria were set
with a minimum of 10 consecutive probes and a minimum size of 700 bp, as
suggested in other studies (Conrad et al. 2010). 700 bp is the suggested theoretical
resolution of this array platform. Using these analysis settings, the number of
segments called varied between 200 and 1000 copy number changes or stretches of
homozygosity per patient, depending on the quality of the results (Figure 11).
Poor-quality results yielded more false-positive changes. The sizes of CNVs ranged
from 700 bp to 14 Mb, with a median size of 1 Mb (mostly stretches of allelic
homozygosity). A second set of filtering was applied by comparing detected
variations within the patient group with an in-house reference set consisting of 19
normal relatives, with an anonymous set of 35 additional DD patients, and with CNV
data available from the DGV database. Each patient had on average 8-20 unique
changes, i.e. changes not present in any refrence group. A third filtering based on
the presence of candidate genes in the aberration was applied, leaving each patient
with 2-4 potentially significant changes. The presence of these changes (n=51) in the
Finnish population was checked against a population cohort of 2065 individuals (The
Institute for Molecular Medicine Finland and The National Institute for Health and
Welfare).
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FIGURE 11. RESULTS OF SNP ANALYSIS. Genomic aberrations (loss, gain, and LOH) of chromosome 16, as seen in 70 patients visualized in the Integrative
Genomics Viewer (IGV) software V.1.5 (The Broad Institute, Cambridge, MA, USA). The image shows clustering of CNVs, such as the gain in 16p11.2, as well as
areas of homozygosity (marked as LOH).
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9. VALIDATION OF ARRAY RESULTS
Further research is warranted when uncertainty exists regarding the pathogenicity
of the detected aberration. Research of the gene content, the literature, and such
databases as DECIPHER, DGV, and ECARUCA may help. Parental analysis may rule
out CNPs. However, caution must be taken, as some CNVs may show penetrance
variation between the parent and child (Study II). In Studies I-IV, CNPs were ruled
out also by using the DGV database, publication references, and private notes of
previously detected variations in other patients and normals.
Depending on the resolution of the array platform used, it might be necessary to
validate very small aberrations by applying another method of detection.
Determination of the inheritence pattern for the purpose of predictive genetic
counselling may also be indicated. The methods used to validate results depend on
the question asked, whether wanting to confirm the existence of a duplication or
deletion, detect mutations, or explore the mechanism of a rearrangement. The ISCA
Consortium proposes validation of array results by FISH, qPCR, MLPA, karyotyping,
or second array analysis, depending on the CNV detected. In certain instances, FISH
should be performed to clarify possible underlying rearrangements when more than
one deletion or duplication is detected (Miller et al. 2010, Kaminsky et al. 2011). The
need to validate very large aberrations is, however, debatable, as population studies
suggest that the majority of CNPs are less than 100 Kb (Miller et al. 2010).
Validation of the array results of these studies was performed when necessary for
the interpretation. Most validations in Study I were performed on the initiative of
the physicians treating the patient, and thus, confirmations were not carried out
consistently. In Study II, validations were conducted in an effort to elucidate the
inheritance pattern. In Study III, validations were conducted to determine the
pathogenic mechanism of the aberration. In Study IV, validations were conducted to
confirm loss of heterozygosity.
9.1 REAL-TIME Q-PCR (I)
Real-time qPCR (Higuchi et al. 1992) is an efficient and simple method for
confirming deletions and duplications by quantitative measurement of the PCR
product. One or several suitable targets are selected within the affected
chromosomal location such as an exon. Primers for the target and a reference gene
are designed using an online primer designing software such as Primer-blast
(www.ncbi.nml.nih.gov/tools/primer-blast). The amount of product is determined in
real-time during the amplification process by measuring fluorescent probes or dyes
in the reaction. Comparison of the results of the target sequence with a reference
sequence with a known copy number, enables calculation of the initial copy number
of the targeted sequence. More end product indicates a duplication of the target
and less indicates a deletion (Kubista M et al. 2006).
The findings in patients 16 and 17 of Study I were validated by real-time qPCR.
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9.2 MULTIPLEX LIGATION-DEPENDENT PROBEAMPLIFICATION (I, III)
MLPA is a PCR-based method that enables amplification of several DNA targets in
one reaction. Two probes are hybridized to each target sequence, one to each end,
and bound probes are ligated to each other. The probe-pairs have an identical end-
sequence that enables simultaneous amplification of all targeted DNA. The
amplified products are distinguishable because each have a unique size. MLPA is a
suitable method to confirm the copy number of several genes simultaneously. It is
also useful for targeted testing of certain disease genes (Schouten et al. 2002). The
MRC-Holland MLPA kits contain panels of probes targeting genes known or
suspected to be associated with certain diseases such as Charcot-Marie-Tooth and
Duchenne muscular dystrophy.
The findings in five patients of Studies I and III were validated by MLPA using three
different MRC-Holland MLPA kits targeting NSD1, PTEN, and the dyslexia genes
ROBO2, ROBO1, NRSN1, DCDC2, KAAG1 and KIAA0319 (MRC-Holland, Amsterdam,
The Netherlands).
9.3 SEQUENCING (III)
Targeted sequencing is useful for tracking mutations in a gene of interest. If a
duplication or deletion detected by array CGH contains a gene known to cause
disease when mutated, sequencing can reveal the presence of such mutations.
Primers are designed for PCR amplification of the target sequence. A separate set of
sequencing primers are designed to enable sequencing within the amplified
product. During the sequencing process a copy of the DNA template is produced
starting from the sequencing primers by addition of fluorescent nucleotides. Each
time a nucleotide is added to the growing DNA-strand, a distinct fluorescent signal is
omitted and read by the sequencing instrument. As a result, the nucleotide
sequence (A/T, C/G) of the templare is presented. Comparison of the sequencing
results with a known reference enables detection of single-nucleotide changes.
In Study III, the gene of interest (ALDHA5A1) was sequenced for mutations using the
Dye Terminator kit and the 3100 and 3130 Genetic Analysers (Applied Biosystems).
9.4 METABOLIC ANALYSIS (III)
Metabolic analysis is not a conventional way of confirming array results. However,
testing the effect of an aberration on the function of the gene product, metabolic
studies may be warranted.
In Study III, the enzymatic activity of Succinate semialdehyde dehydrogenase
(SSADH) was measured from blood lymphocyte cell cultures using
spectrofluorometry. The metabolic waste product γ-hydroxybutyrate (GHB) was 
measured from urine samples using combined gas chromatography-mass
spectrometry.
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9.5 MICROSATELLITE MARKER ANALYSIS (IV)
In Study IV, validation of detected regions of segmental UPD was performed by
microsatellite marker analysis in the candidate area. Comparison of microsatellite
markers of parents and child can distinguish whether the genomic segment is
inherited from the mother or father, provided that the parents do not have identical
allelic markers. In case of all markers originating from one parent, segmental UPD is
confirmed.
9.6 FLUORESENCE IN-SITU HYBRIDIZATION (II)
In Study II, a familial 9q22.2q22.32 deletion showing variable phenotypic
penetrance was examined. In an attempt to exclude mosaicism as a cause of
penetrance variation between father and children, FISH analysis was performed. A
metaphase spread from lymphocyte cells of the father (patient 3 in Study II) was
prepared, and the fluorescently labelled probes (Spectrum orange and green, Vysis,
Abbott Laboratories, IL, USA) were hybridized to the chromosome preparation,
according to standard protocols (van Proojien-Knegt et al. 1982). One probe (RP11-
30L4, 9q22.31) targeting the deleted sequence (Shimojima et al. 2009) and another
probe targeting a normal reference sequence (RP11-31F19, 9p24.3) were used.
9.7 OTHER (I)
In Study I, the parents of 14 patients were analysed by array CGH to exclude
inherited CNPs. Further, the parents of one patient were investigated by
karyotyping to exclude CNPs. To exclude technical errors, the samples of four
patients were re-hybridized and analysed.
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RESULTS AND DISCUSSION
The purpose of this work was to evaluate the usefulness of microarray methods in
diagnosing children with idiopathic DDs. The results are encouraging.
An estimated 50% of patients with a DD lack a diagnosis. As has been shown in
several recent publications, new technology has made it possible to diagnose an
additional 10-20% of these patients using array CGH or SNP array analysis, which is a
significant increase (Shaffer and Bejjani 2010b). This was also proven in Study I,
where data from 150 patients with idiopathic DD and a normal karyotype, acquired
using array CGH analysis, yielded an 18% detection rate with copy number changes
likely to be pathogenic in 28 patients.
Distinguishing clinically significant chromosomal aberrations from polymorphisms
can be difficult. Each finding has to be assessed individually, and by studying
parents, databases, and relevant literature, one might reach a conclusion. More in-
depth research of the patient and their family might shed some light on the
inheritance pattern and the pathogenic mechanism of the aberration. This was the
focus of Studies II and III, respectively.
In Study IV, 35 patients with normal array CGH results were evaluated. The
resolution of the SNP 6.0 array was significantly higher than the 244K array.
Nevertheless, no diagnosis could be made based on the results.
10. PATHOGENIC COPY NUMBER ABERRATIONS
The pathogenic aberrations detected by array CGH can be divided into groups:
those that associated with an established syndrome, familial aberrations, and new
findings. The latter group refers to aberrations for which there may be other
publications, but no clear phenotype has emerged, and thus, they cannot be
classified as syndrome-causing.
10.1 CONFIRMING KNOWN SYNDROMES (I)
Most well-known syndromes have first been clinically established, and thereafter, a
common chromosomal aberration or mutation has been discovered. The standard
praxis is to perform targeted analysis of known aberrations, by FISH or sequencing,
after a clinical diagnosis. If the targeted test fails, one may opt to use microarray
analysis for better coverage of the entire genome.
In Study I, aberrations detected in four patients confirmed a suspected or clinically
diagnosed syndrome (Table 4). These includes the Dandy-Walker, Wolf-Hirschhorn,
Sotos, and Bannayan-Riley-Ruvalcaba-Smith (BRRS) syndromes. As an example,
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patient 8 in Study I was clinically diagnosed with Sotos syndrome. The standard
praxis for molecular genetic testing is to sequence the NSD1 gene, which showed no
mutations. Around 90% of individuals with Sotos syndrome have a mutation in
NSD1, and only 10% have a microdeletion encompassing the gene (Tatton-Brown et
al. 2005). An exception is patients of Japanese heritage, of whom 50% have a
microdeletion (Kurotaki et al. 2003). Further analysis of patient 8 by MLPA showed
that the entire gene was deleted. As the patient had severe developmental delay,
atypical of Sotos syndrome, array CGH analysis was performed. Results showed an
approximately 1 Mb deletion of NSD1, in addition to 19 other genes. Deletion of
several additional genes, many of which may be haploinsufficient, presumably
explains the more severe phenotype of patient 8, relative to typical Sotos patients.
With the advent of new technology, today syndromes are first established based on
a common chromosomal aberration, and thereafter, the common clinical features
are characterized. In four patients in Study I, the detected aberration indicated a
recently established syndrome, previously unrecognized during clinical evaluation,
such as Distal 4q-deletion, duplication 9q34, 16p duplication, and 17q21.3 deletion
syndromes (Table 4).
Table 4. Aberrations detected in Study I associated with an established syndrome. Patients are
numbered as in Study I. For more detailed information of each case, please refer to Study I, Tables I
and II.
Patient no. Aberration Syndrome
4 del(3)(q24q25.31) Dandy–Walker
5 del(4)(p16.3p16.2) Wolf– Hirschhorn
6 del(4)(q32q34.1) Distal 4q-deletion
8 del(5)(q35.2) Sotos with ID
15 dup(9)(q34.11) Duplication 9q34
18 del(10)(q23.2q23.31) Bannayan–Riley–Ruvalcaba–Smith
21 dup(16)(p13.3p13.2) 16p duplication
23 del(17)(q21.31) 17q21.3 deletion
The 17q21.31 deletion syndrome is a good example of how a new syndrome was
established in 2006 (Koolen et al. 2006, Sharp et al. 2006, Shaw-Smith et al. 2006)
by collation of patients with the same aberration. It was not until 2008 that the
common clinical features were delineated (Koolen et al. 2008). The cause of the
syndrome is a polymorphic inversion in the parent that predisposes to unbalanced
rearrangement in the child (Koolen 2006). The father of patient 23 in Study I
presented with a polymorphic duplication at 17q21.31, characteristic of the
polymorphic inversion; the patient had the same duplication (Figure 12). Thus, the
deletion seems to be inherited from the father by means of NAHR.
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FIGURE 12. CHROMOSOME 17Q21.31 POLYMORPHIC INVERSION. The figure depicts the
polymorphic duplication (encircled) in patient 23 (A) and her father (B), characteristic of
the polymorphic inversion known in this genomic segment. The daughter also harbours the
pathogenic 17q21.31 deletion, marked in blue to the left.
10.2 FAMILIAL ABERRATIONS (I, III)
In Study I, seven index patients had a familiar pathogenic aberration (Table 5 and 6).
Familial aberrations are often associated with a common phenotype in parent and
child, as was the case for patients 9 and 18 in Study I. In such cases, it is easy to
determine pathogenicity of the detected aberration. However, sometimes parent
and child present with different phenotypes, due to variation in penetrance, leading
to difficult interpretation of the genotype-phenotype correlation (Section 10.2.1).
In one of the families, the mother and her two children presented with mild ID.
Array CGH analysis showed 0.7 Mb duplications of 6p22.2 in all three patients
(Studies I and III, Table 5). The duplication involved ten genes, three of which were
considered (DCDC2, KIAA0319, and ALDH5A1) primary candidate genes for the
phenotype. DCDC2 and KIAA0319 are both strongly associated with developmental
dyslexia, and two other duplicated genes (TTRAP and ACOT13) are also implicated
(Cope et al. 2005, Luciano et al. 2007). However, dyslexia alone would not suffice as
an explanation of the patients’ phenotype. Thus, ALDH5A1 was considered a
stronger candidate gene, and further studies of the effect of the duplication on the
encoded protein, succinate semialdehyde dehydrogenase (SSADH), were
undertaken (Study III). SSADH is an important enzyme of the GABA degradation
pathway, and dysfunctions of SSADH cause SSADH deficiency disorder (OMIM
#271980). In short, dysfunctional SSADH causes accumulation of a toxic by-product,
the neuromodulator GHB, which is associated with mild to severe neurological
damage (Gibson et al. 2003). As SSADH deficiency is a recessive disorder, mutational
analysis of the sequence was performed, with normal results. Further metabolic
studies of the functional level of the enzyme in lymphocytes, as well as the GHB
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levels in urine, showed that all patients had increased levels of SSADH, but normal
levels of GHB. However, the levels of another by-product, SSA, were increased. SSA
is a reactive oxygen species that can cause damage to lipids of the neural tissue,
thus likely causing neurological damage (Gibson et al. 2003, Sauer et al. 2007). The
pathogenic mechanism of the 6p22.2 duplication is hence likely conveyed through
dosage effect; the duplication causes increased SSADH activity, with a subsequent
increase in its by-product SSA, causing oxidative stress of the brain, and thus, the
mild ID of the patients.
Unfortunately, in one family the phenotype of the parent, from whom the
aberration was inherited, was unknown (patient 17).
Table 5. Inherited aberrations. Patients are numbered as in the publications (Studies I, II, or III).
More detailed information is presented in the respective publications.
Article Patient no. Aberration Inheritance
I and III 9, 10, and 11 dup(6)(p22.2) Maternal
I 17 dup(10)(q22.3q23.2) Paternal
I 18 del(10)(q23.2q23.31) Maternal
I 26 and 27 dup(22)(q13.1q13.2) Unknown
II 1, 2, and 3 del(9)(q22.2q22.32) Paternal
I 28 del(X)(p22.11) Maternal
I 29 dup(X)(p11.4) Maternal
I 31 dup(X)(q11.1q13.1) Maternal
X-chromosome aberrations differ from that of the autosomal aberrations as
females may be asymptomatic carriers of an X-linked disorder, having two copies of
the X-chromosome, while males with only one copy will always express X-linked
disorders. In three male patients (28, 29, and 31, Table 6), maternally inherited
aberrations were detected. One X-chromosome aberration, detected in patient 30
(Table 6) was de novo. These aberrations were considered pathogenic either due to
the size of the aberration (patients 28, 30 and 31) or the gene content relating to an
X-linked disease (TSPAN7, patient 29 and OPHN1, patient 31). Also supporting the
pathogenicity were other publications describing similar findings as those in
patients 29, 30, and 31. Since the publication of Study I, a new report has emerged
describing two brothers with severe neurodevelopmental disorder, both harbouring
a 200 Kb deletion of chromosome Xp22.11 involving only the PTCHD1 gene (Filges et
al. 2011). This gene was also deleted in patient 28 of our study.
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Table 6. X-chromosome aberrations. Patients are numbered as in the publications (Studies I, II, or
III). More detailed information is presented in the respective publications.
Article Patient no. Aberration Inheritance
I 28 del(X)(p22.11) Maternal
I 29 dup(X)(p11.4) Maternal
I 31 dup(X)(q11.1q13.1) Maternal
I 30 dup(X)(p11.23p11.22) De novo
10.2.1 VAR IATI ON IN PENETRA NC E (I, II)
It has generally been considered that aberrations inherited from a clinically normal
parent are unlikely pathogenic. This is evidently not the case, as has been described
in reports of incomplete penetrance (Masurel-Paulet et al. 2010). Some pathogenic
deletions are inherited from a phenotypically normal parent. This variation can be
caused by several factors such as non-identical breakpoints in parent and child, the
unmasking of recessive mutations in the intact allele (Čiuladaitė et al. 2011), 
parental mosaicism (Tsubahara et al. 2011), imprinting of an intact allele, or the
two-hit model. Both mosaicism and imprinting are, however, quite rare.
In one family, both children had a 3.8 Mb duplication of 22q13.1q13.2 not present
in either of their phenotypically normal parents (Table 5, patients 26 and 27). In this
family, the aberration may be present in either parent as gonadal mosaicism or one
parent has transmitted a balanced rearrangement in an unbalanced form to the
children. The inheritance of chromosomal aberrations, with various phenotypic
outcomes, has only lately become a recognized phenomenon, and typically this
involves microduplication syndromes (Berg et al. 2010).
In Study II, two daughters and their father (Table 5, patients 1, 2, and 3) had the
same deletion of 9q22.2q22.32, detected by array CGH. However, the father was
cognitively normal, while his daughters had ID. There was also a healthy boy in the
family. Study of the paternal grandparents by SNP array was normal, indicating a de
novo occurrence in the father of this family. SNP array results showed that all three
patients had identical breakpoints.
FISH analysis of lymphocyte cells of the father did not reveal mosaicism; all 80 cells
analysed showed only one signal of the deleted sequence, indicating no mosaicism.
This does not, however, rule out mosaicism in other tissues. There were no
imprinted genes in the deleted region. The most plausible explanation is a second
hit in the daughters, such as a maternally inherited mutation leading to compund
heterozygosity; however, no strong candidate gene was found in the deleted area.
The cause of variable penetrance in this family, thus, remains open.
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10.3 NEW FINDINGS (I, II, III)
In all studies, the biggest challenge was to assess the pathogenicity of detected
variations. The findings that did not fit any of the above-mentioned categories, i.e.
known syndromes or familial or X-linked aberrations, were put in a separate
category termed new findings. As a result, in Study I, findings in 13 patients were
considered new (Table 7); albeit nine of the detected aberrations had been
previously reported by others. The reasoning behind the decision to consider these
findings as likely pathogenic, despite them not being associated with a clear
phenotype, is the following.
The gene content of all aberrations was investigated to see whether any
publications indicated an association of the genes with a phenotypic characteristic.
The heterozygotic loss of five sodium channel genes in patient 2 likely caused the
epileptic seizures of the patient. The heterozygotic loss of nine homeobox D genes
in patient 3 likely caused the mild anomalies of the feet. Very large aberrations,
such as those in patients 1, 7, 13, 14, 16, 19, 20, and 22, are likely to have some
phenotypic affect. Further, there are several publications indicating a 6q-terminal
deletion syndrome, both genotype and phenotype correlating with the findings of
patient 12. In patients 24 and 25, very rare de novo aberrations at chromosome 19
were detected, as described in Section 10.2.1.
For rare aberrations, such as these 13, the delineation of a common phenotype and
establishment of new syndromes will take some time, as there are only a few
reports available for genotype-phenotype correlation studies. Thus, their
pathogenic significance remains open, unless further analysis is undertaken, as in
Studies II and III.
10.3.1 REC IPR OCA L M ICR OABER RATI ONS (I)
Recurrent reciprocal microdeletions and –duplications are frequently caused by
NAHR due to flanking LCRs, which explains the aggregation of aberrations to certain
genomic locations (Shinawi et al. 2010). It has become evident that for most
microdeletion syndromes caused by NAHR due to flanking LCRs there is a reciprocal
microduplication syndrome (Lupski 2009). Microduplications are usually rarer than
the reciprocal microdeletion and may present with a variable phenotype due to
differences in penetrance (van Bon et al. 2011). Despite involvement of the same
genes in both types of aberrations, the genotype-phenotype effect differs due to
the nature of the aberration; deletions causing reduced expression and duplications
possibly cause increased expression of otherwise dosage-sensitive genes.
Two reciprocal de novo aberrations of chromosome 19p13.3 were detected in Study
I (Table 7, patients 24 and 25). The two patients were unrelated. Patient 24 had a
1.25 Mb deletion of 19p13.3 and a relatively severe clinical phenotype, while
patient 25 had a 0.81 Mb duplication of an overlapping genomic area at 19p13.3
and an associated milder phenotype. The duplication breakpoints were flanked by
LCRs and may have arisen through NAHR. The phenotypic effect of these
aberrations was clearly different, with the duplication causing much milder
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symptoms than the deletion. The phenotypic variance is likely due to the
aberrations having different dosage effect, deletions being more harmful. The
duplicated segment may also be inserted into another chromosome, where it may
cause harm to other genes by the mechanism of position effect.
Since the publication of Study I, another report of a 19p13.3 microdeletion has
emerged. In the study of Al-Kateb et al. (2010), a 1.9 Mb deletion was detected that
overlaps the deletion detected in our study. Shared features of patient 24 in our
study and Al-Kateb’s patient are cutis aplasia of the head, mild hearing defect,
minor heart problems, and pre- or periauricular fistulas. These phenotypic
similarities are likely due to similar genotype-phenotype effects of the common
deleted area. Since chromosome 19 is one of the gene-richest chromosomes,
deletions and duplications are likely to affect several genes, thereby causing great
developmental damage. Chromosome 19 aberrations are relatively rare and often
quite small in size.
Comparing the phenotypic effect of reciprocal aberrations allows us to see the
different developmental effects that the genes have, depending on their dosage
level. This kind of comparison may help to elucidate developmental pathways
previously unknown.
Table 7. New findings. Patients are numbered as in Study I. More
detailed information in the respective publications.
Article Patient Aberration
I 1 del(2)(q23.1q23.3)
I 2 del(2)(q24.3q31.1)
I 3 del(2)(q31.1q32.1)
I 7 del(5)(q11.1q12.3)
I 12 del(6)(q26q27)
I 13 dup(8)(q13.3q21.11)
I 14
dup(9)(p21.3)
del(9)(p23p22.2)
I 16
del(10)(q11.22q11.23)
del(10)(q11.23)
I 19 del(12)(q24.31q24.32)
I 20 del(12)(q24.31)
I 22 dup(17)(p13.1p13.3)
I 24 del(19)(p13.3)
I 25 dup(19)(p13.3)
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11. INCREASING THE RESOLUTION (IV)
Even after high-resolution array CGH analysis in Study I, 80% of the patients with
idiopathic DD remained undiagnosed. In an attempt to find a diagnosis for some of
these patients, the analysis resolution was increased by 12-fold. In Study IV, 35
patients with a normal karyotype and a normal array CGH result (by either 44K,
108K or 244K platforms) were evaluated by an ultra-high resolution SNP array
platform (SNP 6.0). Patients were selected and recruited in collaboration with
clinicians based on previous normal array CGH results. Most patients had initially
been investigated by array CGH in Study I. The initial hypothesis was that by
increasing the resolution, small pathogenic aberrations would be easier to detect, as
the probe coverage is denser. Also, potentially, whole-chromosome UPDs or
segmental UPDs would be detected by this method.
11.1 DETECTING ALLELIC HOMOZYGOSITY
Initially, vast amounts of deletions, duplications, and regions of allelic homozygosity
were flagged by the analysis software. After careful filtering of the results, each
remaining aberration was examined for the genes involved and related publications
were sought. The 51 aberrations filtered out from the SNP array results were all
associated with an OMIM disease or phenotype thought to be associated with
patients’ clinical characteristics. After careful evaluation by each patient’s treating
clinicians, decisions were made about whether the aberration was correlated with
the patient’s phenotype. Despite the vast amount of small deletions and
duplications flagged in analysis, in the end none seemed to be associated with the
clinical characteristics of the patients.
However, potentially significant regions of allelic homozygosity (Figure 13) detected
in four patients were correlated with the patients’ phenotype. All the associated
disorders had an autosomal recessive inheritance pattern, and thus, the hypothesis
was that each patient could have inherited a mutation that subsequent to
segmental UPD was present in two copies. This type of reduction to homozygosity
has previously been described as a cause for several autosomal recessive diseases
(reviewed by Engel 2006). However, as a pathogenic event, it is rare.
For the four patients with potential homozygosity reduction due to segmental UPD,
further conformational studies were attempted by microsatellite marker analysis.
However, in all patients, the polymorphic markers indicated biparental inheritance
of the genomic segment, thus ruling out segmental UPD as a pathogenic
mechanism.
Overall, stretches of homozygosity were detected in abundance in the patients of
Study IV. On average, every patient had some 100 homozygotic segments in their
genome. Some homozygotic segments clustered at various genomic locations, as
detected in both the patient and normal group (Study IV, Table III). This clustering
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FIGURE 13. REGIONS OF ALLELIC HOMOZYGOSITY. The image depicts a gene view from the
Chromosome Analysis Suite software (Affymetrix, Santa Clara, CA, USA) showing an area of
allelic homozygosity of a patient in Study IV. The blue dots indicate the allele difference,
the violet vertical bar the homozygotic area, the pink bars the genes, the large dark green
bars the genes causing a disease listed in the OMIM database, the dark green bars the CNV
probes, and the light green bars the SNP probes of the array. The BBS4 gene, associated
with the Bardet-Biedl syndrome is encircled.
indicates the presence of common haplotype blocks, i.e. homozygous regions that
co-segregate from one generation to the next (International HapMap 3 Consortium
et al. 2010). Certain haplotypes may be specific to the Finnish population due to the
founder effect (Kristiansson et al. 2008), increasing the likelihood of parents having
the same haplotype at certain genomic loci.
The results of Study IV do not conform to the findings in two other high-resolution
SNP array studies of DD patients (Berardini et al. 2009, Männik et al. 2010). While in
Study IV the detection rate was 0%, Bernardini et al. reported a detection rate of
6% and Männik et al. one of 23%. This difference may be due to different research
settings. The patients studied by Bernardini (n=70) and Männik (n=77) had initially
been analysed using a lower resolution platform (35 Kb and 55 Kb, respectively)
than the patients in Study IV (8.9 Kb, 13 Kb, and 35 Kb). The aberrations detected in
the other two studies could be detected by using a 244K microarray platform. The
cut-off values applied to analyse the SNP array results were 75 Kb and 50 Kb
respectively, in contrast to 0.7 Kb in Study IV. As such, the two reports do not
indicate supremacy of the SNP 6.0 over the 244K platform. No segmental UPDs are
mentioned in either report.
In two other studies, using lower resolution SNP arrays, both segmental UPDs and
CNVs were evaluated (Bruno et al. 2009, McMullan et al. 2009). Only in the study by
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Bruno could the UPDs of five patients, of the 117 patients studied, be confirmed by
microsatellite marker analysis, whereas in the study of 120 patients by McMullan
none of 121 potential segmental UPDs could be confirmed.
Despite the limited number of patients in Study IV, relative to the four above-
mentioned studies, it seems that increasing the resolution of microarray analysis of
patients with idiopathic DDs beyond approximately 8.9 Kb does not increase the
diagnostic yield significantly.
12. OPTIMAL DIAGNOSTIC WORKFLOW FOR
DEVELOPMENTAL DISORDERS
Investigations, essential for making a diagnosis, start with a clinical history of the
patient and a physical examination. If a syndrome is recognized, targeted studies
can be performed depending on the characteristics of the disease (e.g. karyotype
for suspected aneuploidies, FISH, mutation or metabolic tests). If no clinical
diagnosis is made, these should be followed by microarray analysis (Figure 14) (van
Karnebeek et al. 2005).
Molecular cytogenetic analyses, such as array CGH or SNP methods, should be used
as first-line testing if no clinical diagnosis can be made or if targeted analysis is
negative. Array analysis gives the most accurate information on breakpoints and
gene content. Conventional cytogenetic analyses continue to have a prevailing role
in diagnostics of DDs. What the arrays lack in providing positional information, e.g. if
a duplicated segment is inserted into another chromosome, karyotyping and FISH
make up, and vice versa. High-resolution karyotyping is still the best method to
detect aneuploidies and polyploidies, translocations, and inversions without prior
knowledge of the aberration. Targeted FISH analysis is also optimal when confirming
a clinical diagnosis.
The general conception has been that a genetic diagnosis, such as large
chromosomal aberrations, is more likely to be set for patients with severe DD. This
has, however, been shown not to be the case. Rather, it has now been suggested
that the presence of certain phenotypic anomalies, specifically facial anomalies of
patients, is more often correlated with the likelihood of finding a copy number
aberration (Battaglia et al. 1999, Hunter 2000, van Karnebeek et al. 2005). When
considering a molecular diagnosis, describing the patient’s phenotype in detail is
essential, as this facilitates analysis of CNVs and interpretation of a pathogenic
association.
High-resolution array analysis platforms provide a large amount of data, and thus,
interpretation of detected copy number changes should be made with caution.
Although most inherited CNVs are benign, some may display incomplete
penetrance. A source of variability, mosaicism is not readily detectable by array
analysis. CNV maps are a useful source for filtering out polymorphic variants in
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conjunction with available databases (DGV, DECIPHER, and ECARUCA). Care must,
however, be taken, as these CNV maps are incomplete and do not represent the
absolute truth (Cooper et al. 2007, Sharp 2009). A joint register for variations
detected in the Finnish population would be beneficial for diagnostic work on
patients of Finnish origin, as it is likely that some CNVs are specific to the Finnish
population. This could also bring forth syndromes that are more common in the
Finnish population.
Prioritizing candidate genes is a way of pinpointing aberrations that are likely
correlated with the patient’s phenotype. It also enables distinguishing pathogenic
variations from polymorphic variations. However, this method potentially excludes
new previously undetected disease-causing aberrations.
Diagnostic analyses should continue until all options have been used to detect a
possible chromosomal aberration. The effect of the aberration should be examined
to clarify the genotype-phenotype correlation and to pinpoint candidate genes for
the phenotypic features. For genetic counselling, it is important to establish the
mode of inheritance by parental analysis.
The benefit of increasing the resolution of the arrays in a diagnostic setting reaches
its limit when the data output becomes so large that interpretation is difficult
without bioinformatics assistance. In a diagnostic laboratory, it is possible to use an
ultrahigh-resolution array, if the data is filtered according to set standards, such as
minimum size and marker density, providing a restricted view of the data. It is,
however, questionable whether it is then more useful to use a lower-resolution
array, and if necessary, to perform additional testing using for instance, whole
exome-sequencing.
Sequencing will provide information about mutations, but unless the mutation is
known, additional protein studies are required to determine the functional effect of
the mutation.
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FIGURE 14. FLOWCHART OF SUGGESTED USE OF ARRAY ANALYSIS. If clinical evaluation indicates
idiopathic DD or if targeted testing is negative, the patient should be analysed using an
array platform (CGH or SNP). If the array finding is of unknown significance, further studies
should be undertaken to resolve the pathogenicity, such as parental analysis, research of
gene content, and related publications. If a clearly pathogenic aberration is detected,
elucidation of the inheritance pattern, may be indicated to estimate the recurrence risk. If
no aberrations are detected, further studies, such as whole-exome paired-end sequencing,
should be done. All findings of potential significance detected by the array method should
be stored in a database locally and shared globally.
Clinical evaluation
Idiopathic developmental
disorder / delay
Clinically established or
suspected syndrome,
metabolic disorder
SNP/CGH array analysis Targeted testing
Positive Negative
Whole-exome
paired-end
sequencing
PositiveNegative
Unknown significance
Inhereritance
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CONCLUDING REMARKS ANDFUTURE PERSPECTIVES
13. PLATFORM OF CHOICE
When choosing an array platform, it is important to know its pros and cons.
Oligonucleotide arrays are accurate in predicting breakpoints and enable high-
resolution analysis (currently up to 2.6 million probes - Affymetrix). The advantage
of using BAC arrays is that the probes can readily be used for FISH analysis, enabling
easier confirmation of the detected result. However, BAC probes are comparatively
large in size, and therefore, the size of an aberration cannot be as precisely
determined as with the oligonucleotide platform, and small aberrations may go
undetected. Thus, oligonucleotide arrays are recommended for diagnostic purposes.
CGH and SNP array platforms offer different benefits. While both arrays detect
CNVs, SNP arrays also detect long stretches of homozygosity, which may be
important in the transmission of a recessive disease from parent to child. However,
as new arrays are rapidly being presented to the market, it is now also possible to
combine CGH and SNP analysis on a single array platform (Agilent Technologies,
Santa Clara, CA, USA).
Some technical differences exist between the two array platforms used in this study.
CGH arrays are based on a simple comparison of reference and patient signal
intensities; both samples are hybridized to the same array and the differences in
signal intensities are measured. This method of comparison may be biased to
technical errors, such as the comparative success of labelling and the signal intensity
of patient and reference DNA, which can affect the final reading of results. SNP
arrays, in turn, are based on hybridization of the patient sample alone to the array,
and comparison of results with array data from up to 200 reference samples (e.g.
Hap Map or in-house data). This type of database referencing enables a less biased
mode of comparison, and it is easy to have a larger number of references. From this
viewpoint, the SNP array provides less risk of technical errors. Another technical
difference is that the labels used in array CGH are sensitive to degradation by high
ozone levels. This may be a problem, particularly in the summer, when ozone levels
increase. The labels used for SNP arrays are different and are not ozone-sensitive.
The problem encountered with both array platforms is how to filter out CNPs. The
results of the arrays are readily comparable to built-in tracks in the analysis
software of CNVs reported in the DGV database as well as to known disease genes
listed in the OMIM database. The frequency of certain variants is higher in some
populations than in others and may not exceed the minor allele frequency spectrum
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of common CNVs (>10%), while nevertheless being common for that particular
population. According to the HapMap consortium, the average size of CNVs
detected using high-resolution arrays (such as the SNP 6.0) was 7,2 Kb (International
HapMap 3 Consortium et al. 2010). Patient results should optimally be compared
with data from the same population, as only these results will correspond to the
frequency in which common variants are present in that particular population.
The results of this study quite clearly indicate the benefit of using high-resolution
arrays in diagnosing children with idiopathic developmental delay. The maximum
benefit appears to be reached when using a platform with a resolution of roughly
8.9 Kb.
14. ETHICAL ISSUES
During the last few years human genetic research has achieved several milestones,
such as the complete sequencing of the human genome, and discovering the
regulatory function of miRNAs. The tremendous speed by which new discoveries are
published and new technologies are developed is very exciting; but it also has its
downfalls, as the amount of genomic data available is difficult to interpret. One of
the ethical issues in current research is how to use this vast amount of data on a
person’s genome for diagnostic purposes. What information should be revealed to
patients? Is it, for example, acceptable to withhold information on such genomic
changes that could only potentially be harmful in the future (e.g. aberrations in
cancer genes or Alzheimer genes), or should all be revealed? Is it appropriate to
perform high-resolution analysis in prenatal screening tests, and how should this
data be stored?
A subcommittee of the European Society of Human Genetics, the Public and
Professional Policy Committee, has published recommendations on technical, social,
and ethical issues regarding several current topics such as the provision of genetic
testing, screening, and data storage (European Society of Human Genetics, 2003).
15. FUTURE PROSPECTS
Although diagnostic methods evolve rapidly, the number of chromosomal
aberrations detected in molecular laboratories that lead to a diagnosis does not
increase at the same rate. This might be explained by increased knowledge of the
physical aspects of different disorders, which enables clinicians to establish a
diagnosis without unnecessary expensive molecular testing (Hunter 2000). This
emphasizes the importance of reporting new molecular findings and clinical
manifestations, which hastens the emergence of new syndromes, facilitating clinical
diagnostic work and follow-up. It is crucial for all diagnostic laboratories to share
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their findings with the diagnostic community through such databases as DECIPHER
or perhaps through a joint Finnish database.
In view of the considerable phenotypic variation possible with the same CNV,
storing all CNV findings as well as clinical data of each patient in a database is
indicated. By periodically reviewing these findings, patterns of phenotypic
similarities between patients with the same CNVs may emerge.
15.1 THERAPEUTICS
DDs are characterized by signature defects present at birth that are mostly
irreversible. Some symptoms may, however, be treated, e.g. epilepsy or heart
disease. Recent research on other therapeutic treatments involves testing of animal
models with features similar to neurodevelopmental disorders such as Rubinstein-
Taybi, Rett, and Fragile-X syndromes. These experiments involve targeting of the
epigenetic machinery by means of, for instance, histone deacetylation (HDAC)
inhibitors (Abel and Zukin 2008).
HDACs are enzymes that remove the acetyl groups from histone proteins, thus
causing chromatin condensation and subsequently gene expression silencing, as it
prevents the transcription machinery from reaching the genes (Abel and Zukin
2008). Rubinstein-Taybi syndrome is caused by mutations in the CBP protein, which
normally functions as a transcriptional co-activator, but CBP protein deficiency
causes reduced synaptic plasticity. The effect of HDAC inhibitors in mouse models
with Rubinstein-Taybi has been enhanced synaptic activity, and thus, better long-
term memory function (Bourtchouladze et al. 2003). These results offer hope of
improved treatment of certain aspects of DDs in the future.
15.2 UNDIAGNOSED PATIENTS
A diagnosis remains to be found for 80% of the patients with idiopathic DD initially
included in this study. Some of the patients may have a genetic aetiology that has
not yet been detected; the DD of others may be caused by environmental factors or
a combination of both environmental and genetic factors. Some patients may have
a disruption of one or several important genes caused by deletions of
transcriptional control elements or disruptions in epigenetic control mechanisms.
Interpretation of these kinds of disruptions is difficult without any hint of candidate
genes.
Patients may also have point mutations undetectable by array analysis or structural
variations that disrupt important genes. De novo mutations are suggested to have a
larger role in the pathogenicity of DD than previously expected. The most common
cause of monogenic diseases is known to be exonic or splice-site mutations,
affecting the amino acid sequence of the gene. For such disorders, it would suffice
to sequence only coding regions of the genome by whole-exome sequencing
(Kuhlenbaumer et al. 2011).
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Whole-exome sequencing revealed 9 de novo mutations in 10 patients with DD and
normal karyotype and normal array results (Vissers et al. 2010). Six of the detected
mutations are estimated to cause the patients’ phenotypes. These results indicate
that there is a vast amount of information to be sought out by exome sequencing of
patients with idiopathic DDs. Therefore whole-exome sequencing will likely gain
ground in diagnostic laboratories in the near future, once filtering of important
mutations has been made easier, costs are reduced, and advancements are made in
analysis software.
As this project comes to an end, the future lies wide open for further reserach.
Whether it be sequencing or studying structural variations, the missing pieces of the
DNA puzzle remain to be discovered for many patients.
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SUMMARY
The main results of this study are as follows:
1. Array CGH is a valuable method for detecting deletions and duplications in the
heterogeneous group of DDs. In Study I, a diagnosis was made for 18% of the 150
patients previously undiagnosed by standard karyotyping.
2. Assessing the pathogenicity of detected CNVs requires careful research of
available resources, such as literature and databases, in an effort to find a genotype-
phenotype correlation. CNVs inherited from a phenotypically normal parent are not
always benign, and may display variable penetrance in parents and offspring. This
was the subject of Study II, where a del 9q22.2q22.32 was detected in a cognitively
normal father and his two mentally retarded daughters. The cause of variable
penetrance was not found in this family, but is suspected to be a second hit (e.g. a
maternally inherited mutation) in the daughters.
3. To understand the pathogenic mechanism of a new CNV, functional protein
studies may be required. Deletions are clearly pathogenic, when affecting
haploinsufficient genes, but duplications may also have a negative effect on protein
function. This was exemplified in Study III, where a dup 6p22.2 caused increased
production of the SSADH enzyme, which in turn led to increased SSA levels and
likely caused neurological damage in the patients and mild ID.
4. Despite array CGH analysis at a 8.9 Kb resolution, 80% of the patients studied
remained undiagnosed. Increasing the resolution further, to 0.7 Kb by using the SNP
6.0 array, did not yield a diagnosis for any of the 35 patients analysed with previous
normal array CGH results. Despite the limited size of the study cohort, increasing
the resolution of molecular karyotyping infinitely does not appear to produce
substantially more diagnoses. Instead, whole-exome sequencing may be a
preferable option.
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